Register to the newsletter:




Annabelle Ascher
European Commission - Scientific Officer and Policy Developer

Annabelle Ascher is a scientific officer and policy developer at the European Commission, DG Research - Research for the benefit of SMEs.  She is currently working on research policy development, management of research projects in the health/biotechnology sector and the development of innovative funding schemes for SMEs. Before joining DG RTD she held positions at DG Enterprise where she was working on issues of competitiveness of pharmaceuticals/cosmetics and at DG JRC - European Commission Technical Office for Medicinal Products where she was developing several relevant information systems for EU regulatory activities including market authorisation of medicines, pharmacovigilance, harmonisation and dissemination of medical information. Prior to joining the European Commission Annabelle has worked with the pharmaceutical company Bristol-Myers Squibb both in the US and Europe in the field of clinical trials and regulatory affairs. She graduated in mathematics/operational research and economics from Tel Aviv University and in medical statistics from the University of Rochester, NY.  She is fluent in Italian, French, German, Hebrew and English.


Martine Aubry
Lille City - Mayor

Michel Azoulay
Gold Islands Consulting - CEO

Dr. Michal Azoulay is the Executive Director for GoldIslands Consulting and has over 17 years of international pharmaceutical industry experiences. His career has emphasized business strategy, investment planning and intelligence healthcare projects.

Michal was Engagement manager and the Oncology leader for IMS Health Americas and led consulting projects in oncology and other therapeutic areas, encompassing a range of financial, commercial and clinical analyses. He had a broad range of experiences in consulting services for seven years and has managed over 40 consulting engagements for biotechs as well as top ten pharmaceutical companies. He recommended improvements and alternatives solutions to resolve business development problems.

Prior to IMS, Dr Azoulay spent nine years at Amgen in Europe, where his responsibilities included the strategic development of oncology drugs and sales force management. Michel oversaw and implemented a variety of training and communication programs, designed clinical studies and organized scientific sessions related to Amgen’s portfolio of oncology products.
Earlier in his career, Dr Azoulay was a Research Assistant at the laboratory for Research and Fight Against Cancer and at Inserm. Michel had a significant role in monitoring clinical studies and conducting fundamental research. In addition to his research back ground, Dr Azoulay practiced medicine for 2 years during which he worked with a wide variety of medical devices, pharmaceuticals products, and information systems.
Dr Azoulay was a Principal and Founder of the Center of Research in Innovation Management (CERECIE) and the Biotech Investment Group (BIG).

Michel holds a MBA with high honors from ESCP-EAP, Paris, France and a MD from Montpellier University School of Medicine, and his fluent in French and English. He was a member of the AARC and the ASCO.

Enrico Bastianelli
Bone Therapeutics - CEO

Dr Bastianelli has acquired a broad pharmaceutical industry experience in fields such as Sales & Marketing, R&D, Licensing, Corporate Development and Strategy. He started his career in the Pathology Department of the Erasmus University Hospital in Belgium, before joining Procter & Gamble Pharmaceuticals in Marketing in 1996, where he was involved with the marketing of ethical and over-the-counter drugs in the field of bone diseases. In 1999, he went on to become a Consultant for McKinsey & Co, where he spent most of his time on strategic and organizational missions for major pharmaceutical as well as for biotechnology companies all over Europe. From its creation in 2002 until mid-2006, Dr Bastianelli has worked as VP Corporate Development for ProSkelia, the Aventis spin-out focused on bone diseases and hormone disorders, who became ProStrakan, after the merger with Strakan, a Scottish specialty pharma company.  At ProSkelia, as a member of the executive committee, he was responsible for the management of the R&D product portfolio, the resources allocation and planning, the alliances and collaborations and the downstream integration. He was one of the main contributors to the merger with Strakan. Since June 2006, he is the Chief Executive Officer of Bone Therapeutics, a Belgian-based Cell Therapy company, specialized in Bone Diseases.

Binah Baum
Bio Negev cluster - founder

Dr. Binah Baum is the founder of BioNegev, Israel’s leading innovation cluster. She is a member the steering committee of CEBR and champion of CEBR’s Incubation Special Interest Group. She also serves as managing director of TMI (Technology Maturation & Incubation) which focuses on the promotion and externalization of technologies from Israel to Europe for incubation, expansion finance and commercialization. TMI is working in association with TTT TRxPansion Technology Transfer of Basel.  
Dr. Baum is highly skilled in the university - industry interface, in the commercialization of new biomedical technologies and in the creation and nurturing of early-stage companies and incubator start-ups. She began her professional career at the VC firm of Adler & Company in New York where she actively participated in the establishment of Biotechnology General Ltd, Israel's first biotech startup company Ever since, and throughout her professional career, she has been actively involved in the enrichment of the Israeli bio-community and sharing its best-practices in innovation and entrepreneurship with the European bioclusters.   Prior to the establishment of TMI she was director of business development at RADBiomed - Israel’s leading biotech incubator, and prior to that she was VP at Medica Venture Partners and business development consultant to Ben-Gurion University’s TTO. She also served as strategic consultant to incubators, biotech and medtech startups in Israel and Europe.
Dr. Baum received her PhD in Life Sciences from the Weizmann Institute and her MBA in Management of Innovation from Columbia University. She also took part in ECBD, the European Course for Biobusiness Development, ECPM Basel, Switzerland.


Philippe Baumgartner
Avecia Biotechnology - Associate Director of Early Phase Development

Mr Baumgartner graduated from Applied Biological Sciences at the University Paris XII in Paris, France, 1997. Philippe went on to obtain a Master degree (MSc) in Biotechnology and Chemical Engineering from the University of Manchester Institute of Technology (UMIST), UK, in 1999. He worked for two years at the Scottish Crop Research Institute in Dundee, Scotland, developing production processes at pilot-scale for the production of plant proteins using Pichia pastoris and Escherichia coli as expression systems. Philippe joined Avecia Biologics in Billingham, UK, in 2002. After 6 years working as a Process Development Scientist and a Senior Project Leader, he is currently holding the position of Associate Director of Early Phase Development. His key responsibilities are to design and supervise work programmes on behalf of their customers for the development, optimisation, and scale-up of processes for the manufacture of biopharmaceuticals from pre-clinical phase to phase III.


Anthony Baxter
Cyprotex - CEO

Dr Anthony Baxter was the founding Chief Executive Officer of Argenta Discovery Limited, a leading drug discovery services and proprietary therapeutics company backed by substantial venture capital investment. In less than four years from the company’s start-up in 1999, he grew services revenue to over £9 million which included building a pipeline of novel therapeutic programmes. He then led the successful merger of the business with biotech company, Etiologics Limited. Prior to this, Dr Baxter was Chief Scientific Officer of Oxford Asymmetry International PLC and helped build the business from an early stage company to its flotation on the London Stock Exchange and then to its eventual merger with Evotec in 2000 at a valuation of £316 million. Dr Baxter led the turnaround of deltaDOT Limited, a proteomics/genomics platform technology company, which involved fundraising of £8.3 million. Since June 2008 he has been Chief Executive Officer of Cyprotex PLC an AIM listed company which is a preclinical discovery/development contract research organisation with a core focus in analysing the ADME (absorption, distribution, metabolism and excretion) and pharmacokinetic properties of potential new drugs. He is currently also Non-Executive Chairman of Equinox Pharma Limited, an Imperial College spin out company focussing on development of ‘machine learning’ for iterative and multi-parametric drug discovery projects.


Christian Béchon

Christian Béchon, born in 1959, is a graduate of the Ecole Centrale des Arts et Manufactures engineering school, Institut d'Etudes Politiques de Paris, he became a public auditor on leaving the Ecole Nationale d'Administration in 1988.

Before joining LFB, he held the following positions:  Deputy General Secretary of the public auditing body for French Social Security from 1988 to 1992, then General Secretary of IPSN, the French Nuclear Protection and Safety Institute from 1992 to 1994.

From April 1994 to May 1995, he was Deputy Chief of Staff to André Rossinot, then Minister for Public Service under Prime Minister Edouard Balladur.

After a short spell as General Secretary of CNES, the National Space Research Centre (May-June 1995), he was Chief of Staff to Elisabeth Hubert, Minister for Public Health and Health Insurance under Prime Minister Alain Juppé from June to November 1995. He was then an investigator on the Central Investigative Committee on the cost and yield of public services (1996) before returning to public auditing in April 1997. At the same time, he was General Delegate to the Industrial Forum Circle from 2000 to 2002. From 2000 to 2004, he has been Deputy Chief of Staff to Francis Mer at the Ministry of the Economy, Finance and Industry under Prime Minister Jean-Pierre Raffarin from 2002 to 2004, as well as Chief of Staff to Industry Minister Nicole Fontaine. Senior Advisor for the Boston Consulting Group in 2005, Christian Béchon was appointed Chairman and Chief Executive Officer of LFB S.A. in 2006.


Anne Lise Berthier
BioPharmaceutiques - Chief Redactor

Anne-Lise Berthier is chief-editor of BioPharmaceutiques, dedicated internet newsletter that interprets health biotechnology’s news from both a pharma perspective and a resolutely European angle. She is also senior editor at Pharmaceutiques, the first pharma magazine in France. Prior to starting with Pharmaceutiques in 2000, she has written on a regular basis with several biotech and technical publications (Biofutur, AgroPermances…). She has a scientific background in biochemistry, genetics and microbiology and has got a postgraduate certificate in genetics and physiology of microorganisms.

Réjane Bihan
Atlantic Biotherapies - Biotechnology Projects Manager

Réjane BIHAN provides support for building and monitoring R&D projects in the healthcare & biotech sectors.  Her activity is dedicated to help cluster members providing comprehensive project support - from consortium building up until the award of funding. She is also the first contact for biopharmaceutical industry major accounts.
As a life science PhD, Réjane also holds a Masters in Marketing from the University of Rennes. Her professional experience includes stints with a consultancy firm and a biotech start-up.

• feasibility studies/R&D project formalization
• partner searching/consortium building
• assistance with R&D project proposals
• R&D project accreditation
• project submission to funding bodies
• R&D project monitoring

Kevin Bilyard
Nine-TZ Healthcare Venture - Principal & Co-Owner

Kevin has broad industry experience gained over more than 25 years in new product development, product strategy and corporate development roles with two major pharmaceutical companies (SmithKline Beecham and AstraZeneca), a drug delivery company (Quadrant Healthcare) and several earlier stage biotechnology companies. He has managed various aspects of new product development with particular emphasis on early stage proof-of-concept work. He led projects to improve efficiency of the development process and portfolio management while at Zeneca Pharmaceuticals; authored several articles and speaks at conferences and training events on various topics linked to pharmaceutical product development and risk management.
He gained direct senior level IPO experience as Product Development Director at the time of the London Stock Exchange listing of Quadrant Healthcare where, in a subsequent role as Corporate Development Director, he was also intimately involved in activities related to trade sale, M&A, formation of joint ventures and fund raising.
Kevin has been a director of or advisor to several emerging biotech and pharmaceutical services companies in Europe and USA and is a co-founder of Nine-TZ Healthcare Ventures, a trans-Atlantic business and corporate development consultancy with offices near Manchester, UK and in Newark, New Jersey.


Robert Blakie
ERA Consulting - Director of Regulatory Affairs and General Manager (UK)

Robert has over 30 years experience of working in regulatory affairs for the pharmaceutical industry (in both a subsidiary environment and at a Corporate level). His regulatory experience is broad and global (including Europe and the USA) and covers a variety of products including biologics and small molecules; devices; veterinary products; small molecule generics and biosimilar products from the quality, non-clinical and clinical perspectives. His therapeutic area experience includes oncology, cardiovascular, neurology, immunology, respiratory/pulmonary, anti-infectives. Robert has served on regulatory committees within industry associations such as the Bio Industry Association, European Generics Association and the Association of the British Pharmaceutical Industry.

Jean-François Bloch
Proteus - Deputy General Manager

Jean-François Bloch is one of the company’s founders and a renowned expertin Industrial Property. Proteus is an internationally recognized biotechnology company which focuses on the discovery, engineering and manufacturing of proteins of industrial interest, and on the development of innovative protein-based bioprocesses. The efficiency of Proteus' technology platform has been demonstrated by the successful track record of the company in the life sciences industry, including healthcare, chemistry (fine or specialty chemicals), environment and bioenergy.

Prior to joining Protéus, he was responsible for the Intellectual Property and Licensing department at ORIS Industries, the biomedical subsidiary of the French governmental agency CEA (Commissariat àl'Energie Atomique).

Jean-François Bloch received his Ph.D. in pharmaceutical science from the Louis Pasteur University of Strasbourg, France. He is also a graduate of CEIPI (International Center for Intellectual Property, Strasbourg).

Jean-François Bloch’s name appears on the INPI lists of persons qualified in Industrial Property and on the list of mandated representatives of the OHMPI EEC brand. He is a former member of the SACEPO (Standing Advisory Committee of the European Patent Office). Since 1991 he taught Industrial Property at the Faculty of Science of the Universities of Paris, Nîmes and Montpellier, at the Faculty of Pharmacy of the University of Angers and at EAP (Ecole Européenne des Affaires), covering international technology management and transfer.

Jean-François Bloch is the author of numerous articles in many areas of IP management and technology transfer. He is regularly called on by public or trade institutions to participate in the reflection on IP in biotechnologies.


François Bocquel
Phenopro - Head of Operations and Business Corporate

Francois Bocquel is Head of Operations and Business Corporate at PhenoPro since January 2009.He studied Medicine at the University of Bordeaux II from 1978 to 1984.Trained as a general practionner, he graduated in 1985 in Business Management and Pharmaceutical Regulation ( Dess IPIB –IAE ). His whole professional experience has been acquired over 20 years in Pharmaceuticals business. He held positions as Marketing Director and Business unit manager for big Pharma industries as Schering AG , Warner Lambert , Pfizer and UCB. He has been driven by business objectives on highly competitive markets and had an active contribution in introducing new drugs in Hospital and Primary care prescriptions reference list. With PhenoPro he is very committed to” start up”: Transform a concrete business from science and   academic expertise acquired in Phenotyping validated processes to commercial objectives. To accelerate the process decision of drug development at the earliest preclinical stage  Phenopro aims to be a drug evaluation platform -for Pharmaceutical Companies -dedicated to standardized  or tailored phenotyping assays / protocols.In less than 2 years a specific building will be engineered for these activities where 20 new collaborators will join PhenoPro.


Kerstin Bode-Greuel
Bioscience Valuation - Founder and Managing Partner

Kerstin M. Bode-Greuel, MD, Ph.D., is founding and managing partner of Bioscience Valuation with offices in Germany and the USA and of Bioscience Market Research based in the USA. Kerstin has over 18 years’ experience in pharmaceutical R&D and strategic marketing, covering virtually all therapy areas. She has worked for Bayer AG in a number of senior positions including R&D and global project management. At Bayer, Kerstin was member of the task force responsible for the implementation of value-driven portfolio management. Prior to founding Bioscience Valuation, Kerstin worked as an independent management consultant for five years.

Kerstin advises pharmaceutical and biotech companies on issues related to valuation and risk and portfolio management. She is widely known as an expert in financial project and portfolio evaluation, R&D and commercial risk minimization, and in real options analysis. Kerstin developed and enhanced modern, quantitative project and portfolio management methods that are based on thorough financial analyses. Those financial analyses provide a direct measure of value creation. In addition, Kerstin assists her clients in implementing an efficient portfolio management process. Kerstin publishes in peer-reviewed journals and has authored two expert reports for SCRIP (‘Financial Project Evaluation and Risk Analysis in Pharmaceutical Development’ and ‘Real Options Evaluation in Pharmaceutical R&D’). She is Associate Lecturer at the University of Essen for the subject of financial valuation and portfolio management. Her workshops and presentations dealing with advanced portfolio management techniques are very well received at international conferences.

Kerstin studied medicine in Marburg (Germany), Nottingham (UK) and Cambridge (UK) and was educated in corporate finance at the Wharton School of the University of Pennsylvania (USA). She is a member of the Decision Sciences Institute of Atlanta (USA).


Conny Bogentoft
Karolinska Development - CEO

PhD in Medicinal Chemistry and Associate Professor in Pharmaceutical Chemistry, Conny Bogentoft  has acquired over 30 years of experience in the pharmaceutical industry, in senior R&D management positions and as a member of the Board of Directors of a number of companies, and has demonstrated his ability to successfully plan, implement and develop clinical and business strategies. Previous appointments include Vice President of Astra Arcus, President of Kabi Invent, Research Director at Aco Läkemedel and Chairman of the Swedish Academy of Pharmaceutical Sciences.



Jean-Bernard Borfiga
Les Laboratoires Servier - Head of Scientific Collaboration & Business Development

J.B. Borfiga joined Servier in 1993. He is the Head of the Scientific Collaboration and Business Development Division.
His responsibilities include R&D collaborations, mergers and acquisitions, and Business Intelligence.
Prior to Servier, J.B. Borfiga was VP Business Development for Zynaxis Cell Science, Inc., CEO of BioEurope SA and VP of Corning Glass Works / Biotechnology Division. J.B. Borfiga graduated from the Ecole Nationale Supérieure de Chimie de Paris, and hold a Doctor Engineer Degree from Paris University. Further education includes Harvard Business School. J.B. Borfiga is member of the Board of HBS Healthcare Worldwide and HBS Club de France. He has launched the HBS Healthcare Alumni Association in Europe.
J.B. Borfiga is also member of the Board and the Scientific Board of the Foundation of the House of Chemistry of France. Last March 2007, J.B. Borfiga has been elected Chairman of the Alumni Association of the Ecole Nationale Supérieure de Chimie de Paris. As such he has been elected Vice President at the Board of the School and Member of the "Conférence des Présidents de Paritech Alumni" (the 10 top Paris schools of Engineers including Polytechnique, Ecole des Mines de Paris etc…).


Luuk Borg
Secretariat Eureka - Head

In 2006, Luuk Borg was seconded to Brussels by the NL Ministry of Economic Affairs, to manage the new joint EU-EUREKA Eurostars Programme for R&D-performing SMEs. He later accepted the post as director of the EUREKA Secretariat. Under his leadership EUREKA continues in its ambition to perform as the best platform for research-performing businesses in Europe, with results that benefit society at large.

Borg began his career as a consultant and account manager on EU-funded and other research projects, specifically targeting the participation of SMEs. He then joined the Senter/EU-Liaison Agency where, as managing director, he oversaw the merger of EU-Liaison with Senter. Borg was also responsible for establishing the NL Office for European Science and Technology (NEST).

Simone Botti
Rad Biomed - Director of Business Development

Dr. Botti received his Ph. D. in Chemistry from the Weizmann Institute of Science – where he received the Dov Elad Award for Structural Biology – and was NIH–ADDP Fellow at Northwestern University Medical School in Chicago.

Dr. Botti brings to Rad Biomed his extensive experience and skills in international business development, his top level global network. Before joining the Incubator, Dr. Botti was Senior Director of Business Development, EMEA for Cogenics, one of the worlds' leading providers of genomics services. Prior to that, Dr. Botti was Managing Partner of AltioraVentures, a European-Israeli investment banking boutique specialized in cross border M&A and international business development, focused on high technology and life sciences.

Dr. Botti also founded and managed Biostrx, a nanobiotechnology company which he partnered with IT giant TATA Consulting Services (TCS), to provide global services in Drug Discovery. Dr. Botti is Head of the German Israeli Life Sciences Committee of the Israel-Germany Chamber of Industry and Commerce and Vice President of the Italy-Israel Chamber of Commerce.

Dr. Botti fluently speaks Italian, English, French, Spanish and Hebrew, and has acted as a consultant for major European financial institutions and governmental agencies in matters of technology transfer and technology financing.


Douwe Breimer
Leiden University - Professor of Pharmacology

Douwe D. Breimer is Professor of Pharmacology at Leiden University and he was the Rector Magnificus of the University from 2001 till 2007 and also President from 2005 till 2007.    He studied pharmacy at the University of Groningen and obtained his PhD at the University of Nijmegen in 1974. In 1975 he was appointed full Professor of Pharmacology at Leiden University.    He  is the founder of the Center for Bio-Pharmaceutical Sciences at LeidenUniversity and  was Director of Research of the Leiden/Amsterdam Center for Drug Research from 1991 till 2000.  He is (co)author of more than 500 scientific articles in the areas of (clinical) pharmacokinetics, drug metabolism and biopharmaceutics and he supervised more than 50 PhD students. He has been on the editorial board of numerous scientific journals en he received several scientific awards and distinctions, among which are seven honorary doctorates from foreign universities (Boedapest, Gent, Uppsala, Tokyo, Pamplona, London and Montreal).  He is  member of the Royal Netherlands Academy of Arts and Sciences, Foreign Associate Member of the Institute of Medicine (IOM) of the National Academy of Sciences USA, Foreign Member of the  Académie Nationale de Pharmacie in Paris, Fellow of the American Association of Pharmaceutical Scientists (AAPS) and Fellow of the American College of Clinical Pharmacology (ACCP). He is one of the founders of the European Federation for Pharmaceutical Sciences (EUFEPS) and  of the League of European Research Universities (LERU). He is currently chairman of the Board of Life Sciences Partners, a venture capital company in Amsterdam and he serves on the supervisory boards  of the Technical University Delft, University College Cork and the University of Leuven. 


Garold Breit
Manitoba University TTO - Executive Director

Garold Breit is a leader with extensive experience in technology-based organizations.  His career began at Revlon, where he served as a Senior Marketing Manager and member of the Corporate Acquisitions Team.  Mr. Breit has served as the president of biopharmaceutical companies and has launched three successful intellectual asset programs at dramatically-different academic institutions (Creighton University, the University of South Alabama and at the University of Texas).  He has consulted with Boys Town National Research Hospital on complex intellectual property matters since 1993.

Today, Gary is the Executive Director of the Technology Transfer Office (TTO) at the University of Manitoba in Winnipeg.  The University of Manitoba is the Province’s leading comprehensive, research-intensive academic institution and has an enrollment of more than 28,000.   The TTO has recently completed four record-breaking years (invention disclosures, transactions, Federal Grants, start-ups and revenues).


Jeannie Brooks
BioMimetic Therapeutics - Associate Director, Clinical Affairs

Jeannie Brooks, RN, BSN is currently the Associate Director of Clinical Research at Biomimetic Therapeutics (BMTI), in Nashville, TN.  Joining the company in February 2009, Jeannie brings with her 30 years experience as an RN, with over 20 years in clinical research working in oncology, stroke, cardiac and orthopedic disease programs.  Over the years she has worked as a consultant to hospital systems that were building research programs, providing support for the growth and development of programs of all sizes.  Since 2001, she has been on the industry side of clinical research working with medical devices in stroke, cardiology and orthopedics.  From the sponsor side, Jeannie has worked on international trials and has a wealth of experience related to the challenges and lessons learned as a US sponsor for European studies.  In her current role, she is responsible for all EU studies at BMTI, and enjoys the challenges and rewards these opportunities provide.

Nicolas Carboni
Alsace Biovalley - General Manager

Nicolas Carboni is General Manager of Alsace Biovalley - one of the three world class competitiveness clusters in Life Science and Health in France - leading the development of the life science sector in the Alsace Region. After a first contractual period of three years, the Alsace Biovalley cluster has been recognized as one of the most performing cluster in France, and recommended by the Boston Consulting Group to the French Government as a “World Class Cluster” following the audit mandated by the Ministry of Industry on competitivness clusters in France. Alsace Biovalley is also the coordinator of the tri-national Life Science cluster Biovalley – one of the oldest biocluster in Europe - spamming from Basel to Fribourg and Strasbourg.Before joining Alsace Biovalley in 2006, Nicolas was head of the Technology Transfer Office (TTO) of Université Louis Pasteur of Strasbourg (ranked in the first 100 in Shanghai ranking), managing over 12 million euros of collaborative R&D contracts. In that position, he led the creation of Conectus, the federation of all TTOs for public research organizations in Alsace (4 universities, 3 engineering schools, National Research Council, Health National Research Council), securing over 3 millions euros of funding for the Conectus “proof of concept” fund.Before moving to Alsace, Nicolas has lived 13 years in Canada, 10 of which working at the interface of public research and science - both from the public and private side – focussing on spin-off creation, technology transfer, and R&D management. During that period, he has worked for the National Research Council of Canada, Universities, the Government of Quebec, as well as large industrial groups such as Suez Environment.In 1997, he was co-founder of Bio Artificial Gel Technologies (reached FDA approval in 2008), one of the first spin off from Université du Québec à Montréal. In 2004, he was appointed Director of “Centre d’Analyses et de Recherche” (over 180 employees), affiliate from Université Louis Pasteur. He strongly contributed to the creation of Phenopro, the first Spin off from the Mouse Clinic Institute (founded by Pierre Chambon), and became – and still is - the President of Phenopro when it was created in 2007.Nicolas has been sitting for 5 years on the national jury of the national competition for start up creation, organized by the Ministry for Higher Education and Research, and OSEO. He was also a member of two working groups for the definition of the National Strategy for Research and Innovation, launched in 2009 by President Nicolas Sarkozy. He was guest speaker for numerous conferences, both in France and abroad.Nicolas Carboni has a background in Law, Business (Marketing) and Engineering (Innovation Management) obtained both in France and in Canada.

Dirk Carrez
EuropaBio - Director Industrial Biotechnology

Engineer in Chemistry and Agricultural Industries (Bioengineer) of the Ghent University (1984), Dirk Carrez holds a PhD in Agricultural Sciences, which he prepared at the Laboratory of Molecular Biology of Prof. Dr. ir. Walter Fiers (Ghent University - 1989).
Since September 2004, he is Director Industrial Biotechnology at EuropaBio (The European Association for BioIndustries), where he is coordinating the activities in the area of industrial biotechnology and the “biobased economy”, as well as some horizontal issues (such as research & innovation, SMEs & access to finance”).
Between 1999 and 2004, he was Secretary-general of BelgoBiotech (the Belgian biotech industry association, now, and also Director Innovation & Product Policy of Fedichem (the Federation of the Belgian Chemical Industries, now Essenscia).
He has been Responsible Care® and Product Stewardship Manager (Chemicals Sector) at SOLVAY S.A. (1997-1999), Senior Research Assistant at SOLVAY Research & Technology at the Department of Industrial Fermentation (1990-1997), and (Senior) Research Assistant of the National Fund for Scientific Research (FNRS, Belgium) in the Laboratory of Molecular Biology of the Ghent University (1984-1990).
Dirk Carrez is also Vice-Chair of BIAC’s Biotechnology Committee (Business and Industry Advisory Committee to the OECD), Vice-Chair of OECD’s Task Force for Industrial Biotechnology, member of the European Commission’s Ad-hoc Advisory Group for the Lead Market Initiative for Biobased Products, and member of the Steering Committee of the European Biofuels Technology Platform.


Emmanuel Chantelot
European Biopharmaceutical Enterprises - Executive Director

Emmanuel Chantelot is the Executive Director of European Biopharmaceutical Enterprises (EBE), a trade association headquartered in Brussels, which represents 65 research-based biopharmaceutical companies of all sizes operating in Europe. As the voice of biopharmaceuticals in Europe, EBE interacts with European institutions on healthcare policies and issues that are specific to biotechnology-derived medicines. EBE also operates as the biotechnology arm of EFPIA, the European pharmaceutical industry federation.

Before joining EBE in June 2006, Emmanuel occupied senior management positions in global and European trade associations in various industry sectors. From 1997 to 2004, he was the Managing Director of the World LP Gas Association, a global business association in the energy sector operating out of Paris, and from 1992 to 1997, Manager in Eurometaux, the European trade association for the non-ferrous metals and mining industries in Brussels. He was also General Manager of AGS, an international professional services firm, from 2004 to 2006.

Emmanuel has got a 17-year track record in advocacy, communications, business strategy management and lobbying in relation to the European Institutions, various UN agencies, the World Bank, and numerous national governments worldwide.

Emmanuel Chantelot obtained his two Masters degrees in molecular biology and in chemical industry management / biotechnology from the Free University of Brussels and received business management education at Northwestern University in Chicago.

Jean-François Chatal
Arronax - Scientific Advisor

Jean-François Chatal is a Distinguished Professor of Nuclear Medicine at the University of Nantes, France.In 1975 he created a research team devoted to diagnostic (scintigraphic imaging) and therapeutic (radioimmunotherapy) use of radiolabeled monoclonal antibodies in oncology. This research team was a part of a larger group specialized in immunology and oncology and affiliated to INSERM (National Institute of Health and Medical Research) and University of Nantes. The first patient with a colorectal carcinoma was injected in Nantes with a 131I-labeled anti-tumor monoclonal antibody in June 1981.At the end of the 1980’s, he developed a strong collaboration with Immunotech company in Marseille for the preclinical and clinical application of an original and innovative pretargeting technology based on the use of unlabeled bispecific antibody and radiolabeled bivalent hapten and which had just been patented by Immunotech. After a clear documentation of the efficacy of this technology in diagnostic application (immunoscintigraphy) at the begining of the 1990’s, the first phase I radioimmunotherapy study was initiated in 1996 in patients with medullary thyroid cancer and small cell lung cancer.  Recently, in 2006, a paper published in the Journal of Clinical Oncology reported, for the first time, a survival benefit of pretargeted radioimmunotherapy in an advanced solid tumor (medullary thyroid carcinoma).Jean-François Chatal initiated, with 2 other  colleagues, the project of installation in Nantes in 2008, of a high energy/high intensity cyclotron, termed ARRONAX, for the production of innovative radionuclides for nuclear medicine research in Europe.He wrote 180 original papers and presented more than 100 invited lectures.


Désiré Collen
ThromboGenics NV – Founder and Chairman

Désiré Collen holds a M.D. degree (1968) and Ph.D. degree in Chemistry (1974) from the University of Leuven, Belgium. He served as Director of the Molecular Cardiovascular Medicine Group (comprising the Center for Molecular and Vascular Biology of the K.U. Leuven, and the Vesalius Research Center of the Flanders Institute for Biotechnology) in Leuven, Belgium until September 2008. He has research interests in the molecular biology and pathophysiology of hemostasis and thrombosis, the development of novel thrombolytic and antithrombotic agents, the pathogenesis and treatment of atherosclerosis, and gene targeting and gene transfer studies of the cardiovascular system, and translational research in cardiovascular drug development. His team initially developed t-PA, currently the most effective drug for thrombolytic therapy of acute myocardial infarction.

Dr. Collen has co-authored over 650 research papers and has received four honorary doctorates (Erasmus University, Rotterdam, The Netherlands; Free University Brussels, Belgium; University of Notre Dame, IN, USA; Mediterranean University, Marseille, France), and several scientific awards including the Francqui Prize (Belgium) in 1984, the Prix Louis Jeantet de Médecine (Switzerland) in 1986, the Bristol-Myers-Squibb award for Cardiovascular Research (USA) in 1995, and the Health Prize of the Interbrew-Baillet Latour Fund (Belgium) (jointly with P. Carmeliet) in 2005.

Dr. Collen was the Founder of and until August 2008 Chief Executive Officer of ThromboGenics, NV, a biopharmaceutical drug development company listed on Euronext Brussels. He continues to serve as the Chairman of the Board of ThromboGenics NV.


Magnus Corfitzen
Sunstone Capital, Life Science Ventures - Investment Director

Magnus Corfitzen is an Investment Director in Sunstone Capital in the Life Science team where he has been since the incorporation in 2007. Magnus’ activities span broadly from drug development to medtech and diagnostics companies and he currently serves on the board of Nordic Vaccine, CMC Contrast, Vivostat and Dentofit. He has extensive experience in all stages of the investment cycle ranging from deal sourcing and incorporation of companies to operational development as well as licensing and M&A transactions.
Before the establishment of Sunstone Capital, Magnus worked for more than four years at Vaekstfonden investing in early stage companies. Before moving into venture capital he was a Portfolio Manager at Danske Capital (a leading Scandinavian asset manager and part of the Danske Bank group) responsible for worldwide investments in publicly listed biotech and medtech companies. Magnus has also been with McKinsey & Co advising clients in Scandinavia on a range of areas, but primarily within asset management and pharmaceuticals.
 Magnus holds a Master Degree in Mathematical Economics from University of Aarhus which included studies at Harvard University.

Antoine Cournot
Eucrof - President

Antoine Cournot is having a 30 year experience in Clinical Research in France and in Europe.After being Nurse in Gerontology, then CRA, Antoine was Director of Operations and President of Therapharm Research, a French CRO.Since January 2009, Antoine Cournot is President, European Business Operations of Research Pharmaceutical Services.Antoine Cournot was also President of AFCROS (Federation of French CRO) and since December 2006, he is President of EUCROF (European Federation of CRO)



Michel de Baar
OctoPlus - Senior Manager Business Development

Michel started his career as Ph.D. student at the University of Amsterdam and specialized in molecular virology of HIV. Following his Ph.D. graduation, he went to work for Primagen, an Amsterdam-based company active in development and marketing of diagnostics using a nucleic acid testing platform, where he has taken up roles varying from project and program manager to business development manager. After a 6 year career at Primagen, he moved to OctoPlus where he became full-time employed in business development, and got promoted to senior management after 1 year. OctoPlus is a drug delivery company focused on formulation development services, drug delivery technologies and controlled release product development as well as manufacturing of final drug product for parenteral administration. Michel’s role at OctoPlus is focused on managing acquisition of projects within a new and existing global customer base in the pharmaceutical contract service industry as well as managing a range of both in- and out-licensing projects with a focus on technology licenses.


Willy de Greef
Europabio - Secretary General

Willy De Greef is a plant biologist with extensive experience in tropical crop breeding (through research management positions in the Democratic Republic of Congo, Malawi and Cameroon) and in technology transfer related to agricultural biotechnology. He has been head of regulatory affairs for two biotechnology leaders, Plant Genetic Systems in the 1980s, and Syngenta Seeds from the late 1990s until 2003. He has been involved in the policy and public debate around agricultural biotechnology (OECD, UNIDO, Biodiversity Convention, Cartagena Biosafety Protocol) and in the development of the regulatory framework since 1986. He has contributed to the development of rational regulatory frameworks for biotechnology for developing countries and in capacity building for biotechnology researchers in the developing world in biosafety assessment and regulatory compliance. Recently he has been head of regulatory affairs and new projects for D1 Oils Plant Science, a biofuel company.


Rudy Dekeyser
VIB Technology Transfer - Manager

Rudy Dekeyser is managing director of VIB and manager of VIB’s technology transfer department.

He is involved in the strategic management of an important patent portfolio, the negotiation of R&D and license collaborations with companies, the establishment of biotech start-up companies and the exploitation of bio-incubators. He has been board member at Devgen, CropDesign and Ablynx nv, and is board member at ProNota nv, Actogenix nv, Solucel OY, CardioBiosciences sa, Bio-Incubator Leuven nv, EMBLEM (the EMBL tech transfer company) and FlandersBio (the Flemish biotech cluster).

He is also co-founding board member of the European Association of European Science and Technology Transfer Professionals (ASTP), chairman of Valorisation Advisory Board of NGI and guest professor “innovation management” at the University of Ghent. Dr. Dekeyser obtained his PhD in biology at the University of Ghent.


Daniel Denis
Secor - Senior Partner

Daniel Denis joined SECOR in 1984 and is the senior partner responsible for the Economics practice. His areas of specialization include regional and industrial development, life sciences and venture capital. He has worked with public and private corporations in Canada and Europe, assisting them in identifying major strategic issues, defining objectives and directions as well as designing action and implementation plans.
In life sciences, Daniel has coordinated or contributed to numerous industrial, cluster, competitive and regional analyses projects and advised on public policy issues. He has also been in charge of or has collaborated with numerous task forces dealing with life-science issues. He has conducted many assignments for major pharmaceutical companies, biotech firms, venture capital organizations, health institutions, regional clusters, research centers and government bodies. He is the co-author of: “Building a Pharmaceutical Industry: The Quebec history”.
Over the last few years, he has done some research on academia/industry partnerships in drug discovery. He has helped define new types of collaboration, some of which have been implemented recently in Quebec.
A specialist in economic analysis, Daniel has published works in public finance and is regularly invited to comment on government budgets and policies. Daniel holds a B.A. and a M.Sc. in Economics from the University of Montréal. Prior to joining SECOR, Mr. Denis worked as a financial economist for a major Canadian bank.


Richard Dennett
Eden BioDesign - Head of Consultancy Services

Richard holds the position of Head of Consultancy Services and is responsible for direct client liaison on consultancy projects and for the effective management and execution of Eden’s global consultancy project portfolio.  Richard has a broad experience of pre-clinical process development associated with the design, optimisation and scale up of processes from concept to GMP manufacturing scale.   He has advised on process strategies internationally, especially in the implementation of automation systems and innovations for industrial biopharmaceutical applications.  

Richard also has applied experience in the commercialisation of research and has actively participated in the formation of a number of new of start-up companies.  Richard successfully project managed the validation and construction interface of the National Biomanufacturing Centre, Liverpool UK.


Gilles Devillers
Pages Partners - Pharm-D MBA

Gilles has built a solid expertise in pharmaceutical development and business development for drugs and biologics (including vaccines) with their primary presentations for the parenteral, oral and respiratory administration routes.

He has been involved with and led activities in licensing, strategic marketing, technology valuation of drugs and delivery systems in early and late development stages. He also has practical experience in the development of pharmaceuticals and has worked in the nuclear medicine ward of the Grenoble hospital. Gilles has worked on projects in phases from pre-clinical through to life-cycle management in a range of therapeutic areas and drug delivery systems.

Prior to co-found Bio Elpida (April 2009), a Contract Manufacturing Organisation specialised in cell culture, and his own consultancy venture (Pages Partners) he was responsible for European and world wide business development and strategic marketing at Becton Dickinson Pharmaceuticals and Valois Pharmaceuticals. Prior to this, he was a scientist, team leader and business development manager at SmithKline Beecham and Quadrant Healthcare.

Gilles is a doctor in Pharmacy and has a post graduate engineering diploma and an MBA with 2 majors in innovation marketing and corporate finance.


Frédéric Druck
BioWin - Director, Communication & International Relations

Frédéric Druck has a degree in journalism and communication from the Université Libre de Bruxelles where he began his carer as an assistant lecturer. He then developed his professional expertise in corporate communication and public relations in positions of responsibility at employer organisations. He acquired his knowledge of the health sector while working at Merck Sharp & Dohme and Interel, a Belgian pubic relations consultancy that works with various pharmaceutical companies, where he was in charge of the medical department. At BioWin, Frédéric has responsibility for the cluster’s communication, networking activities and international relations.



Jean-Baptiste Dumas
Helios Bioscience - Director

Jean-Baptiste has been an internationally recognized leader in genomic-based drug development for over 20 years. Jean-Baptiste is a  founder of Helios BioSciences, which he incorporated as the CEO in May 2002. During the period of 1994-2000, Jean-Baptiste was the manager of the "Gene Library" business of GENSET, one of the pioneering genomic companies with an IPO in 1996 and considered to be the largest and fastest growing biotechnology company in France, which was sold in 2001 to Serono. Jean-Baptiste joined GENSET in 1994 as its 50th employee, when this young French Biotechnology company terminated its research programs on anti-sense and transformed into one of the first genomic companies worldwide. Jean-Baptiste created and managed the department of R&D focused on gene regulation and cDNA libraries which at its peak had up to twenty-seven commercial, IP or academic collaborators and was the most successful R&D department of the company. Jean-Baptiste was responsible for the initiation of the commercial contract with Genetics Institute. He also played a key role in re-organizing the CERES program that (after the reorganization) he directed as the scientific leader for two years to its successful completion. He is the inventor on various patents, including patents on genomic methods and thousands of individual genes having a potential therapeutic application. The total deal size under his management was up to 41M€. His scientific curiosity and interest in commercializing his ideas, started early as being a PhD graduate student at CNRS in Gif/Yvette from 1990-1994, where he developed and patented innovative technologies to characterize and discover gene regulatory regions, an area of tremendous scientific interest up to now in the post genomic area dominated by mRNA expression arrays. After his PhD, he worked for the GENXPRESS team managed by Charles Auffray at Généthon, one of the first genomic institutes in the world. He is  author and co-author of 14 scientific publications and books with reading committee. He is also the inventor of more than 30 patents in the field of genomics and transcriptomics.



Yann Echelard
GTC Biotherapuetics - VP of Research and Development

Yann Echelard, Ph. D., Vice President Research and Development, GTC Biotherapeutics, Inc. has over 25 years of research experience, the last 15 years' pertaining to transgenic research and the development of protein expression systems. He received his Ph.D. in Microbiology and Immunology from the Université de Montréal and completed his post-doctoral studies at the Ludwig Institute of Cancer Research (Molecular Oncology), the Roche Institute and Harvard University (Developmental Biology) where he was involved in the isolation and characterization of Hedgehog genes, the first identified vertebrate morphogens. In 1994 he joined GTC Biotherapeutics (at the time, Genzyme Transgenic Corporation), initially leading the Embryology group.  There, in 1998, he has led the team that first performed goat somatic cell nuclear transfer. He has also participated in the development of ATryn® the very first transgenically-derived biopharmaceutical to obtain regulatory approval. Currently, his responsibilities at GTC include the management of recombinant plasma protein programs (coagulation factors and antitrypsin programs) and an antibody with enhanced ADCC (TG20). 


Mikael Englund
Cellartis AB - Senior Scientist

Edgar Fenzl
FGK Clinical Research - Managing Director, Founder and Principal

Edgar Fenzl has spent over 30 years in pharmaceutical medicine, including work in pharmacokinetics, gastrointestinal pharmacology, First-in-Man studies, cardiovascular pharmacology, oncology, pain, migraine, CNS drugs, immunology, infectious diseases, OTC, medical devices, clinical research management, phase I clinical research unit design and management, large and small company experience, national and international phase II and III clinical studies.
For the last 30 years, he has assumed additional managerial responsibilities in large and small companies.
His educational background includes an MD degree from the University of Regensburg and the Technical University of Munich (1979) and a Ph.D. from the Technical University of Munich (1984).

Matilde Fernandez
Bio-Lliberis Research &Development - Head of I+D Department

Matilde Fernandez Rodriguez has a Mater Degree in Microbiology and a PhD in Biological Sciences in 2004 from the University of Granada. She has had several positions at the Microbiology Department of the University of Granada and at the Alimentary and Pharmabiotic Centre of the National University of Ireland.  From December 2007 she is Head of the Innovation & Development (I+D) Department at Bio-Iliberis R&D where she supervises the work of a PhD student and a technician. She is team leader in a number of National and European projects in which Bio-Iliberis R&D is participating. She has a number of publications in international peer-reviewed journals. Her research lines include bacterial responses to biotic and abiotic stresses, including response to antibiotics and toxic chemicals; host-microbe interactions and microbial ecology. Bio-Iliberis R&D is also interested in soil and water protection with special emphasis on metagenomics and biodiversity.

Matilde Fernández is ad hoc reviewer for a number of scientific journals and is contributing on a regular basis to the Editorials of Microbial Biotechnology, highlighting research articles that are published in the journal. She has ample laboratory experience in molecular biology and microbiology.


Bruno Flamion
University of Namur - Full Professor, Head of the Laboratory of Physiology and Pharmacology

Bruno Flamion, M.D. (internal medicine, nephrology). Research Fellow at the National Institutes of Health (USA) in Bethesda, MD, USA, 1988-1992 and with the Belgian National Fund for Scientific Research, 1992-1996. Bruno Flamion is Full Professor and Head of the Laboratory of Physiology and Pharmacology at the University of Namur, Belgium. He works as a medical expert for the Belgian Federal Agency for Medicines and Health Products (FAMHP) and the European Medicines Agency (EMEA) in London where he is chair of the EMEA/CHMP Scientific Advice Working Party.


Göran Forsberg
Active Biotech AB - VP Investor Relations & Business Development

Göran Forsberg has a Ph. D. in Biochemistry from the Royal Institute of Technology in Stockholm. He has had various positions in R&D within KabiGen, Pharmacia, University of Adelaide and Active Biotech. He has authored approximately 40 peer reviewed articles primarily within biochemistry and oncology. Dr Forsberg is currently VP Investor Relations and Business Development at Active Biotech and is also responsible for the clinical development of Active Biotech's prostate cancer drug TASQ. Active Biotech is a listed Swedish Biotech company with 5 projects for treatment of autoimmunity or cancer in mid to late stage clinical development.

Sibylle Gaisser
Fraunhofer Institute Systems and Innovation Research – Coordinator Tessy project

Dr Sibylle Gaisser studied bioprocess engineering, molecular biology, genetics and microbiology at the Universities of Stuttgart, Swansea and Freiburg, graduating in 1994 with a Master in Technical Biology at the University of Stuttgart. Her Master thesis dealt with the production of shikonin in plant cell cultures. In 1998 she received her PhD at the Eberhard-Karls-University Tübingen, Faculty of Pharmacy, for research in the field of modular biosynthesis of antibiotics and the resistance mechanisms in a Streptomyces. From 1998-1999 she worked as the assistance of the CEO at the Biotechnology Agency Baden-Württemberg.
In July 1999 she joined the Fraunhofer Institute Systems and Innovation Research as a Project Manager and Senior Scientist in the Competence Center ‘Emerging Technologies’. Her main research interests are the sustainable development in biotechnology and the health sector; impacts of innovations in life sciences on society, economy and ecology, and improved knowledge transfer in life sciences.

Sibylle is a lecturer for bioprocess technology and microbiology and was the project coordinator of the FP 6 funded project “Towards a European Strategy for Synthetic Biology (TESSY)”.


William Gallagher
OncoMark Limited - CEO/CSO

1. Vice-Principal of Research and Innovation, UCD College of Life Sciences
2. Associate Professor of Cancer Biology, UCD School of Biomolecular and Biomedical Science
3. Conway Fellow, UCD Conway Institute

Prof. Gallagher originally graduated from the Department of Biochemistry, UCD in 1993 with a 1st Class Joint Honours degree in Molecular Genetics and Biochemistry. Subsequently, he obtained a PhD in Molecular and Cellular Biology from the Cancer Research UK Beatson Laboratories in Glasgow. In 1997, he moved to Paris to undertake a Marie Curie Individual Fellowship at Rhone-Poulenc Rorer (currently Sanofi-Aventis). Afterwards, he returned to Ireland upon receipt of an Enterprise Ireland Post-Doctoral Fellowship (1999-2000) and, subsequently, a Marie Curie Return Fellowship (2000–2001). In 2001, he was employed in a permanent capacity as College Lecturer at UCD within the former Department of Pharmacology. In 2005, he was appointed Senior Lecturer within the UCD School of Biomolecular and Biomedical Science and was promoted to Associate Professor of Cancer Biology in 2006. In September 2009, Prof. Gallagher took up the position of Vice-Principal of Research and Innovation at the UCD College of Life Sciences. He is also a Conway Fellow at the UCD Conway Institute. In 2007, he co-founded OncoMark Ltd., which is a private company centred on the development and application of biomarker panels and associated technologies, on both tissues and biological fluids ( A major focus of Prof. Gallagher’s research work is the identification and validation of candidate biomarkers of breast cancer and melanoma, with particular emphasis on translation of transcriptomic and proteomic datasets into clinically relevant assays. In addition, his team utilises lentiviral-based approaches to investigate the functional relevance of candidate tumour progression-associated genes at both in vitro and in vivo levels, as well as engages in preclinical evaluation of novel anti-cancer agents.

Prof. Gallagher currently co-ordinates an FP6 Marie Curie Transfer of Knowledge Industry-Academia Partnership Programme, Target-Breast (, which involves 3 academic and 2 industrial partners across 3 EU countries (running from 2006-2010). In addition, he co-ordinates an analogous FP7 Marie Curie Industry-Academia Partnership and Pathways Programme, Target-Melanoma, which involves 9 partners (5 academic/4 industrial) across 5 EU countries and runs from 2009-2013. Prof. Gallagher is also co-PI of a major Science Foundation Ireland-funded Strategic Research Cluster, Molecular Therapeutics of Cancer (2009-2014). Prof. Gallagher has received a number of awards based on his research work to date, including the BACR/AstraZeneca Young Scientist Frank Rose Award in 2004 and the St. Luke’s Silver Medal Award in 2008. Prof. Gallagher has had productive collaborative interactions with a variety of other industrial partners throughout his research, and has filed multiple patents.

William Haddad
Biogenerics, Inc. - Chairman&CEO

William (Bill Haddad), Chairman/CEO of Biogenerics, in the media is called "the father of the generic industry."  He initiated and negotiated Hatch-Waxman that, after thirty years, opened the door to generic competition in the United States (1985) and savings are estimated at ten to fifteen billion dollars each year. Nine years ago he introduced generic biotech to the United States. For a dozen years he served as Chairman or CEO of the generic trade association in the United States and as CEO/manufacturing and Vice Chairman of the Board of Schein Pharmaceuticals, then the largest generic company in the United States. He created a consortium of generic companies, MIR, to help create a modern pharmaceutical industry in the former Soviet Union.

As a journalist with the New York Post and Herald Tribune, Bill Haddad earned a dozen major awards and was nominated for a Pulitzer Prize for his reporting on poverty and the slums in New York and his exposes of political corruption. At the Tribune, he tracked down secret cartel minutes and exposed and destroyed the worldwide cartel controlling tetracycline prices resulting, at the time, the largest corporate fines in the pharmaceutical industry ($200 million).

In 2000, he volunteered to lead a team to work with Dr. Yusuf Hamied of Cipla to reduce the price of AIDS medicines in poor countries. Cipla offered a rational regime of one tablet taken twice a day combining the three most important AIDS drugs, replacing a brand regime from three companies that required use several times a day and reduced the price from $15,000  a year to a dollar a day (now under $100 a year). WHO quickly recommended the "triple" as line treatment for AIDS. Now a million and a half patients are kept alive by using affordable generic AIDS medicines, up from the 50,000 at the start of the campaign. The US PEPFAR program for AIDS was created as a result of these actions and is currently a fifty billion dollar contribution. Although President Bush created in his 2003 State of the Union, the White House staff successfully blocked generic use for three years. That story is related in "If Truth Be Told" that can be obtained from Bill Haddad. He is currently involved in developing sources for generic flu medicines.

Bill Haddad has edited or written five books.

Thomas Hankemeier
Netherlands Metabolomics Consortium - Scientific Director

Thomas Hankemeier is full professor for Analytical Biosciences at the LACDR, Leiden University, since 2004. His research is aiming at innovative analytical tools for metabolomics-driven systems biology in personalized health strategies. In recent years he developed tools to detect, quantify and identify as many as possible metabolites in mammalian biofluids, tissues and cells. His research aims at improving multi-dimensional separation methods, improving the interfacing to mass spectrometry, miniaturizing sampling devices and separation systems using micro/nano-technology and developing methods for the identification of metabolites. In collaboration with clinicians, biomedical researchers, biostatisticians and other –omics researchers he works on better (early) diagnosis and interventions for cardiovascular disease, diabetes and neurological diseases. He is the director of the recently established Netherlands Metabolomics Centre ( He is member of the Board of Directors of the Metabolomics Society. He has a MSc in chemistry and a PhD in analytical chemistry.  From 1996 to 2004 he was responsible as a scientific product manger at the department of Analytical Sciences at TNO for research in the fields of food safety, food quality and metabolomics.


Mellor Hennessy
AstraZeneca - Global Portfolio Strategist

Mellor Hennessy has held various portfolio management responsibilities in Development, Commercial and Discovery parts of Zeneca and AstraZeneca for the past 15 years. He was part of the portfolio integration task force when Astra and Zeneca merged in 1999.

More recently, Mellor has taken on performance management responsibilities. He co-leads the AstraZeneca R&D Performance Network and is part of the team that defines the content of the AZ R&D scorecard.

He has recently led a project to stretch AstraZeneca’s portfolio management ambitions. His professional interest is innovation in management practice.  He is a physicist, a graduate of Oxford University and gained his PhD at the Cavendish Laboratory, University of Cambridge.

Rouget Henschel
Foley & Lardner - Partner

Dr. Rouget F. (Ric) Henschel is a partner with Foley & Lardner LLP.  His practice focuses on counseling clients in patent matters, representing clients before the U.S. Patent and Trademark Office (USPTO), litigation, and licensing. Specifically, his practice includes validity and freedom-to-operate opinions; due diligence investigations; negotiating and interpreting patent licenses; procuring domestic and foreign patents; post-grant reexamination and reissue proceedings; and interferences.  His practice also includes litigation in federal and state trial courts and appeals before the USPTO Board of Patent Appeals and Interferences and the U.S. Court of Appeals for the Federal Circuit. His experience includes technologies such as pharmaceuticals, biotechnology, polymers, nanotechnology, and cosmetics.

Dr. Henschel returned to Foley & Lardner LLP after a clerkship with Judge Randall R. Rader of the U.S. Court of Appeals for the Federal Circuit.  A frequent public speaker, he is a faculty member of the Pharmaceutical Education & Research Institute and the Asia Pacific Legal Institute.  Dr. Henschel is a contributing editor of the Federal Circuit Bar Journal.   He is fluent in French and German.

Kowid Ho
AFSSAPS - Biologicals/Biotechnology Unit

Kowid HO has been reviewing the quality of biotechnological medicinal products at AFSSaPS (Agence Française de Sécurité Sanitaire des Produits de Santé) for the last 10 years.  He has authored many assessment reports and scientific advices, and regularly participates at EMEA's Biotechnology Working Party, Biosimilar Working Party, PAT team and other ad'hoc groups.




Andre Hoekema
Galapagos - SVP Corporate Development

Galapagos (Euronext: GLPG) is a drug discovery and development company with small molecule programs in bone and joint diseases, bone metastasis, cachexia, anti-infectives and metabolic diseases. It has established multi-year strategic alliances with GSK, Janssen Pharmaceutica, Eli Lilly and Merck.
Andre Hoekema joined Galapagos in March 2005 from Invitrogen Corporation, where he was Managing Director of Corporate Development Europe.  He brings 20 years of biotech experience from positions at Molecular Probes Europe (Managing Director), Crucell (Director of Business Development), DSM Life Sciences and Genentech, Inc (R&D).  He has a PhD degree from Leiden University, he authored more than 30 scientific publications and he is the inventor of over 20 series of issued patents.


Stephane Hogan
European Commission - Head of Coordination Unit, Directorate Health, DG Research

Stéphane Hogan is currently Head of the Coordination Unit in the Health Directorate of DG Research. His unit is responsible for planning and coordination of the Health research programme in the EC's 7th Framework programme, which foresees €6.1 billion in grants for Health research over the period 2007-2013. His unit is also responsible for cross-cutting issues such as industry participation, international cooperation, ethics and communication.Prior to that he spent several years in research in Ireland and Belgium, then worked in journalism and in corporate communications in France, before joining the European Commission (DG Research) in Brussels in 1996. Stéphane holds a degree in science (Genetics) and an MSc in Biotechnology from Trinity College Dublin (Ireland), as well as an MBA from The Open University (UK).


Roger Holdsworth
UCB - Head, R&D Portfolio Management

Roger Holdsworth, who originally qualified as a physiologist, joined Celltech in R&D in 1982 and subsequently worked as an R&D Group Leader in a joint venture company (Boots-Celltech Diagnostics) developing and marketing clinical diagnostics. During that time he took responsibility for budgeting activities and planning activities. He became a Project Manager within the Development Division of Celltech in 1989, where he managed a number of alliance projects with major Pharma partners. 
When arequirement to develop a portfolio analysis system was identified in the Celltech organization, Roger was closely involved in the design and specification of the tools to be used and subsequently carried out analysis based on financial and other attribute to support decision making by senior management.
This role continued following the acquisition of Celltech by UCB in 2004 and has developed to focus on the use of quantitative and qualitative data in portfolio management and in particular on the provision of recommendations to senior governance bodies within the company. Roger now works within the Global Operations and has particular responsibility for the review of the late stage (post proof of concept) pipeline based on financial and other measures.


Ora Horovitz
BGN Technologies - VP Business Development

r. Ora Horovitz serves as VP Business Development and IP Manager at B.G. Negev Technologies Ltd. (BGN), the Technology Transfer Company of Ben-Gurion University of the Negev, Beer-Sheva, Israel. Dr. Horovitz is a graduate of Bar Ilan University and the Hebrew University and holds a Ph.D in Molecular Biology from the Weizmann Institute of Science. Dr. Horovitz joined BGN in 1997 following 20 years of Research and Development positions in academy and industry in Israel and the US and 5 years of International Marketing and Business Development.




Manfred Horst
Merck Sharp & Dohme France - Director Licensing & External Research Europe

Manfred Horst studied medicine in Munich, Montpellier and London, with a specialisation in Allergy and Immunology. MBA INSEAD, Fontainebleau.Manfred has almost 20 years in the healthcare industry - Clinical Research, Strategic and Operational Marketing, PharmacoEconomics and most recently Licensing and Business Development. He has worked at Merck & Co. (MSD) since 1999.




Jacqueline Hunter
GlaxoSmithKline - SVP Science Environment Development

Dr Jackie Hunter has worked in the pharmaceutical industry for over 20 years, after carrying our post doctoral research at St George’s Hospital Medical School in London.  For most of her industrial career she has focussed on the discovery of drugs for serious neurological diseases such as Parkinson’s disease, multiple sclerosis and Alzheimer’s disease.  She has worked for Glaxo, Smith Kline and French, SmithKline Beecham and is currently at GlaxoSmithKline based in the UK. In 2002 she was appointed Head of the Neurology and GI Centre of Excellence for Drug Discovery (CEDD).  In this role she was responsible for 350 scientists (medicinal chemists, DMPK personnel and biologists) and clinicians based in the UK, Singapore and USA.
The CEDD was focussed on the discovery and development of new therapeutics for neurodegenerative disease, pain and gastrointestinal disorders.  This resulted in over 15 proofs of concept in 5 years and several transitions to full development.

Dr Hunter has published over 130 scientific papers and served on a number of industrial and academic boards and is currently a member of the BBSRC council.  In 2008 she moved to become Head of Science Environment Development with a remit to develop a pre-competitive research agenda and new ways of working with academia and other publically funded bodies. In her current role she is actively involved in driving forward the Innovative Medicines Initiative for Europe and is an IMI Board member.



Maria Isaac
EMEA - Member of the Scientific Advice team

Dr. Maria Isaac is a member of the Scientific Advice team at the European Medicines Agency (EMEA) and has over 15 years of international experience in academic, clinical and regulatory fields. Her career has focused on novel and innovative pharmacological, economic and clinical treatment of mental illness.At EMEA, she has developed and maintained her interest in the clinical impact of innovative and advanced treatments with particular emphasis on biotech and stem cell therapies, not only for mental and neurological illness, though disorders of the nervous system remain her passion.Before EMEA, Maria was a Consultant Psychiatrist in the UK National Health Service for more than 5 years, gaining a deep insight into the impact of mental illness on patients, their families and the wider society. As an honorary senior lecturer in psychiatry at the Institute of Psychiatry (a position she continues to hold), she built a clinical research programme and was the Co-Director of the Psychopharmacology Evaluation Unit at University Hospital Lewisham, a Unit that quickly achieved international recognition for its approach to novel pharmacological treatments of depression and the psychiatric aspects of chronic pain. She also had an active role in training and education, co-ordinating several international meetings and collaborations.A native of Spain, Maria qualified in medicine at the University of the Basque Country and obtained a Master’s degree from Temple University Philadelphia (USA). She has wide experience in molecular biology research, both in the USA and UK, as well as in clinical research. She obtained her PhD in psychopharmacology in record time at the University of London (Guy’s Hospital 1998), collecting along the way a postgraduate diploma in economics from Birkbeck College, also in the University of London. She is fluent in Spanish and English and has a good working knowledge of French and Portuguese.

Heung-Chae Jung
Korea Research Institute of Bioscience and Biotechnology - Director of Intellectual Property Management Department


Heung-Chae is Director of Intellectual Property Management Department at Korea Research Institute of Bioscience and Biotechnology (KRIBB) in Korea.  He has been with KRIBB for 18 years and has moved to his current role last year. Before that he has worked in Bioprocess Engineering Division where he had a wide range of experiences including molecular evolution of proteins, microbial physiology, metabolic engineering, and process development for protein and biochemical production. He has also experienced two times with founding biotech startup companies and managing R&D center of the company.


 He was born in Korea and has degrees of Ms in Biotechnology from Korea Advanced Institute of Science and Technology (KAIST) in Korea, and PhD in Biochemical Engineering, Microbiology and Biotechnology from University of Technology of Compiegne in France. He joined KRIBB just after graduating from KAIST.


His current responsibilities are with Connect KRIBB programme that involve identifying best-in-class technologies/solutions in KRIBB and transferring them to domestic companies as well as global players of pharma. He is also developing new business opportunities with technologies from KRIBB such as technology transfer, founding new startup companies, and raising funding from big pharma, government, and others.




The Korean Research Institute of Bioscience and Biotechnology (KRIBB) is only one government-funded research institute in the biotechnology field in Korea. KRIBB, finding itself at the center of the nation's biotechnology development, is striving to contribute to the improvement of public health and to the development of the bio-industry by undertaking essential research to further our understanding of living phenomena, and high-end biotechnological research in varying fields ranging from health care and food to new biomaterials, the environment, novel energy sources, and so on. We would like to be a progenitor of biotechnological development and national prosperity founded on the spirit of progressiveness, challenge, and innovation.



Bjoern Colin Kahrs
Merck Sereno - Patent Manager

Colin has joined the Corporate Intellectual Property Department within Merck Serono S.A. as a Patent Manager in 2007, after several years with the Patent Department of Merck KGaA in Germany. He holds PhD in Organic Chemistry and is constantly involved in all IP related aspects of the company.



Yasmin Karimi-Nejad
Solvay Pharmaceuticals GmbH - Research Scout Technology

Dr. Yasmin Karimi-Nejad is Research Scout Technology in Solvay’s External Research Division Scouting, Portfolio & Alliances. In this role, she is responsible for identifying external opportunities in early drug discovery, focussing on accelerating technologies, target discovery and biomarkers. Her remit also includes establishing alliances with technology partners.Yasmin joined Solvay Pharmaceuticals 10 years ago, and since then held various positions within Solvay’s R&D, in Germany and in the Netherlands. Prior to her current role, Yasmin was responsible for managing the Computer-Aided Drug Design group at Solvay Pharmaceuticals’ Hanover Research site. She is a structural biologist with a PhD in chemistry/biochemistry, and has been a Junior Lecturer at the University of Utrecht before joining pharma industry.


Brian Kelly
Cornell Center for Technology Enterprise and Commercialization – Director

Brian Kelly is the Director of Cornell Center for Technology Enterprise and Commercialization and oversees the technology transfer division serving the Weill Cornell Medical College.  He manages a portfolio of inventions including pharmaceuticals, molecular diagnostics, neural stem cells, gene therapy compositions and methods, and medical devices.

Brian has more than ten years experience in technology licensing both in the United States and Europe.  He has successfully negotiated more than 200 license agreements and has been involved in the formation of approximately twenty start-up companies and is a certified licensing professional. 
Prior to joining the CCTEC, Brian was a technology licensing associate at the University of Minnesota and more recently, the Director of Intellectual Property for New York University’s Office of Industrial Liaison. 

Brian is a native of Liverpool, England and received a B.S. in Chemistry and a Ph.D. in Organic Chemistry from the University of Leicester.  From 1988-1990 Brian was a Smith Kline and French postdoctoral fellow at Yale University.  Upon completion of his fellowship, Brian returned to London to work for an intellectual property law firm earning a M.S. in Intellectual Property from the University of London.

Paul Kemp
Intercytex - CSO and Executive Director

Paul founded Intercytex in 1999 and is its Chief Scientific Officer. He has over 17 years of experience in the commercial development of cell therapies. Prior to founding Intercytex, he was VP Research at Organogenesis Inc. He joined the founders in 1987 as a staff scientist researching into collagen as part of the wound repair stimulant programme Apligraf® and he was later instrumental in its development, manufacture and methods of shipping. He is a principal inventor on several patents related to various regenerative medicines.

Paul has a BSc in biochemistry from the University College of Wales, a doctorate in the chemical structure of skin from the University of Leeds and carried out post doctorate studies on collagen cross-linking in skin at the University of Manchester.


François Képès
Genopole – CNRS Research Director

François Képès is a cell and systems biologist. He is currently studying the dynamics and spatial development of regulatory networks and of secretory endomembranes in cell.

François Képès is a Research Director at CNRS, the French National Centre for Scientific Research. He is the Founding co-director of the Epigenomics Project (Genopole®, CNRS, Univ Evry), an Institute of Complex Studies that is dedicated to the emerging disciplines of Systems and Synthetic Biology. He is an associate member of the Centre for Research in Applied Epistemology (École Polytechnique & CNRS). He has been an Associate Professor of Biology at École Polytechnique. He is the author of over 80 scientific publications and the editor of over 10 books. He has organized numerous international and national scientific events, supervises two current European Action and Project and is also involved in other current Actions. Dr. Képès is the editor of three international journals, referee for 18 others, and is an expert advisor for European, North- and South-American and Middle-East funding agencies. He has also acted as a referee for CNRS and European Commission prospective in Systems and Synthetic Biology, as well as in Complex Systems and in Bioinspiration.


Axel Koch
ElexoPharm GmbH - CEO

Axel Koch is managing director of the ElexoPharm GmbH, an innovative start-up in Saarbrücken/Germany. ElexoPharm is a preclinical CRO offering high quality research in the field of medicinal chemistry. At the same time ElexoPharm runs an own preclinical drug development programme. Besides Axel Koch is head of the Patent Marketing Agency of Saarland Universities since its foundation in 2002. He has broad experience in IP questions related to public research and holds several teaching positions in the field of IP and innovation management. He studied Economics at the European Business School, Saarland University and at the University of Bergamo (Italy) and did postgraduate studies in economics and European law. For the European Union's IPR Helpdesk he was appointed "Member of the Advisory Board".



Jean-Marc Le Doussal
Atlab Pharma - co-founder and President

“JMLD, 46, is co-founder and President of ATLAB Pharma SAS, a biotech start-up developing targeted anti-cancer radiotherapies created in 2008 in Nantes. After his engineering studies at Ecole Polytechnic in Paris, JMLD developed radiopharmaceutical pre-targeting as a PhD student and project leader at Immunotech Marseille and other molecular targeting technologies as a post-doc at University of Lausanne and Pitié Salpêtrière Hospital in Paris. After a MBA in management of technology at Federal Polytechnic School in Lausanne, he started an entrepreneurial carrier as consultant or partner in French and Swiss biomedical start-ups”.

Piet Lens
EFB - Chairman, Section on Environmental Biotechnology

Prof. Dr. Ir. Piet Lens is well known for his groundbreaking work in the field of environmental biotechnology, with a special focus on sulfur and metal removal and recovery. He has authored or co-authored over 185 scientific publications and eight books. Besides innovative research, he is also a leader in capacity-building, organising study-days, conferences, summer schools and short courses.
Prof. Lens trained in Environmental Sanitation, then obtained his Ph.D. in Environmental Engineering at the University Gent (Belgium). He was on the faculty as Associate Professor at the Wageningen University (The Netherlands) and became in 2007 Professor Environmental Biotechnology and head of the Pollution Prevention and Control core at UNESCO-IHE, Delft (The Netherlands).
Prof. Lens is founding Editor-in-Chief of the journal “Reviews in Environmental Science and Bio/Technology” and founding editor of the IWA Publishing 'Integrated Environmental Technology" book series. Prof. Lens’s honors include the IWA Publishing Award (2002) and a prestigious Marie Curie Excellence Grant (2004).


Pierre Noel Lirsac
CEA - Deputy Director Technology for Health

Dr. Pierre-Noël LIRSAC, 45, is Deputy Director of the technologies for health programme at the French Atomic Energy commission (CEA). He is also the present chairman of the Mirror Group and member of the Executive Board of the European Technology Plateform in Nanomedicine. Since January 2009 he coordinates the EuroNanoMed ERA-Net initiative in Nanomedicine.

After A PhD in biochemistry, microbiology and bioconversion, PN Lirsac started as researcher in radiation biology. at the life Science Directorate of the French atomic Energy Commission. From 1996 to 2002 he was Head of the Radiation protection, Biology and Medicine department of the National Institute for Sciences and Nuclear Technologies.
Early 2002 he joined the Directorate for Enterprises of the French Ministry of Industry as Head of the Biotech and Health Department to elaborate an action plan for biotechnology and to support the attractiveness and competitiveness of the bio industry including innovation, R&D, regulatory, economic and fiscal aspects. In 2004, he initiated and chaired during 2 years the ERANET Eurotransbio.

Since End of 2006, he is Deputy Director of technology for health programme. In June 2008 he was elected Chairman of "Adebiotech", the French association of biotechnology actors.



Bertrand Loubaton
GE Healthcare - Director, Pharmaceutical & Academic Collaboration

Bertrand LOUBATON, MBA, Director, Pharmaceutical & Academic Research Collaboration.
He has 20 years experience in Drugs & Medical Technologies in both R&D and marketing. His current responsibility in GE Healthcare involves collaboration between academia and industry, for new technologies & biomarkers development. He’s jointed GE Healthcare in 2005 as European Director Sales/Marketing & Business Development of IMANET a PET research Network of Academic Sites.
Previously, he was Business Development Director at SMV (Gamma Camera), Director of Operations/France Executive Director and Co-founder of the First European clinical sites network (SMO), Marketing/Sales Director of IBAH (Clinical Research Organization; & Product Manager at 3M Pharma & Roussel-Uclaf group.


Anthony Loussouarn
Chelatec -CEO

Dr. Anthony LOUSSOUARN is President & CEO of Chelatec, a Contract Research Organisation specialized in Radiolabelling and Preclinical Studies From the creation of Chelatec in December 2000 to May 2005, Anthony was Managing Director of Chelatec which was co-founded with Dr Jean-François Gestin, Research Director at Inserm Nantes. Prior to participating to this creation, Anthony acquired 3 years of experience as PhD student in this Inserm team and a 2 years post doctoral experience in some Australian Research Organizations where he contributed to research and development in radiopharmacy.He was appointed President of Chelatec in 2005. He developed the programs and grew the business activity to a stage at which, it has been decided the relocalisation of the company on the site Arronax by the end of this year corresponding as well to a new strategic step in the creation of a Radiopharmaceutical branch of Chelatec.

Maurizio Franco Mariani
3A - Head of Research and Development

Maurizio Franco Mariani joined Advanced Accelerator Applications (AAA) as Global Head of Research and Development in April 2009 and is based at the Ivrea (Italy) and Saint-Genis-Pouilly (France) facilities.
From 2007 to 2009, Dr. Mariani served a General Manager of Merck Serono Ivrea, RBM S.p.A and as Global Head of Exploratory/Translational Medicine. From 2003 to 2007, he served as General Manager of Serono Research Ivrea, RBM S.p.a. and as Global Head of Serono Preclinical Development. He also was a member of the Board of Directors of RBM S.p.A.
From 2000 to 2003, he served as Associate Director of Life Sciences at L’Oréal Research and Development in Paris. He was responsible for the selection and development of new active ingredients for the treatment of skin and hair conditions in compliance with specific regulatory requirements.
From 1996 to 2000, he held several positions in Drug Development at Galderma, a dermatology company and joint venture between Nestlé and L’Oréal located in Sophia-Antipolis. From 1988 to 1996, he held several positions in the field of pharmaco-toxicology at the Research Toxicology Centre S.p.a. (Menarini Pharma Group) in Pomezia, Italy.
Maurizio Franco Mariani holds a Degree (Hons) in Medicine and Surgery from the Università degli studi di Roma “La Sapienza”, a Ph.D. Degree in Pharmacology from the Temple University, Philadelphia, United States, and a Diploma (DABT) from the American Board of Toxicology, Washington, United States. He is author, co-author of a large number of publications, and he also participated to the development of new chemical entities.

Philippe Marlière
Global Bioenergies - Co-founder

Chris Mason
University College London - Professor

Chris Mason is internationally recognized to be at the forefront of the emerging field of stem cell and regenerative medicine translation and commercialization. A background in basic science, clinical medicine, bioprocessing and business allows Chris a unique insight and understanding of the challenges facing the regen sector as it grows into a competitive and sustainable global healthcare industry.

Chris holds a Clinical Sciences degree from Imperial College London, a Medical Degree from the United Medical and Dental Schools of Guy’s and St. Thomas’s Hospitals (now King’s College London) and a PhD under the supervision of Prof. Peter Dunnill in tissue-engineering bioprocessing from University College London.

After graduating, Chris specialized in surgery and is a Fellow of the Royal College of Surgeons both of England and in Ireland. Today, after a transition from clinical practice to research, he heads up the Regenerative Medicine Bioprocess Group in the Advanced Centre for Biochemical Engineering at UCL and is on the Steering Committee for the UCL Centre for Stem Cells and Regenerative Medicine. Other accomplishments include being Senior Editor of "Regenerative Medicine" journal, co-founder and co-organiser of the London Regenerative Medicine Network (LRMN) and a member of the founding Steering Committee for the UK National Stem Cell Network (UKNSCN).

Chris is also on a number of national and international committees, working groups and initiatives related to the academic, clinical and commercial advancement of cell therapies and tissue engineering. For example, he has broad range of expertise in commercial consultancy and is presently on the Scientific Advisory Boards of a number of regen companies based in North America. He also led the UK government sponsored “Advanced Cells and Tissue Therapy Global Watch Mission” to the USA in 2006.

Thomas Metcalfe
F. Hoffmann-La Roche - Global Head Personalised Healthcare Portfolio

Tom Metcalfe is Head of Roche’s Personalized Healthcare Portfolio, a joint program between Roche’s Pharmaceutical and Diagnostics divisions, which has the goal of driving Personalized Healthcare concepts forward across the Roche Group. He has been in this position since July of 2007 and previously (from 2004 until 2007) held the position as Head of the Roche Biomarker Program, a program which had similar goals. Prior to these appointments Tom held a number of senior management positions within the Roche Molecular Diagnostics Business Area of Roche Diagnostics, located in Pleasanton, California. These responsibilities included leading the development of a Clinical Genomics business and Business Development (2001 – 2003) and leadership of the Regulatory, Clinical Affairs and Project Management functions (2003 – 2004).  Tom received a B.Sc. in Biochemistry from King’s College, London University in 1982 and an MBA from the Open University, UK in 1996. Tom worked for Roche Diagnostics in Europe from 1993 to 2001 where he held a variety of positions of increasing responsibility with a number of Business Areas of Roche Diagnostics, culminating in his appointment in 1998 as Head of Global Marketing for Roche Applied Sciences. Tom has lived and worked in Switzerland, Germany and California during his career with Roche.


Jean-Claude Muller
Sanofi-aventis - Senior Vice President Prospective and Strategic Initiatives

Amir Naiberg
Yeda - CEO

Amir Naiberg holds an LL.M. degree from the University of Connecticut School of Law and an LL.B. degree from the Hebrew University of Jerusalem. Prior to his appointment as Yeda's CEO, Mr. Naiberg served as Yeda's General Counsel for six years. Before joining Yeda, Mr. Naiberg worked for a private law firm specializing in intellectual property, privacy and cyberspace law.





Susanna Narkilahti
The Regea Institute for Regenerative Medicine - Senior Researcher

Susanna Narkilahti, PhD is senior researcher and group leader of Neuroteam in Regea Institute for Regenerative Medicine, University of Tampere, Finland. Regea engages in research in cell and tissue engineering, the focal areas being stem cell research and research combining stem cells and biomaterials towards clinical applications.

Susanna Narkilahti received her Master degree in University of Oulu, Finland and PhD degree in A.I.V Institute for Molecular Medicine, University of Kuopio, Finland. She has performed post-doctoral fellowship in Institute of Reconstructive Neurobiology, University of Bonn, Germany.

The research focus of Dr. Narkilahti is the development of stem cell therapies for neurological deficits. The process includes the production of suitable neural cell populations to testing in animal models and to translation of the process to GMP-production. The main interest is in development of stem cell therapies to spinal cord injury, stroke, cortical brain injuries, and multiple sclerosis. In addition, Dr. Narkilahti’s team focus on in vitro functional characterization of human derived neural networks for tissue model and graft design purposes.

Klaus Nickisch
Evestra - CSO

Klaus Nickisch is a Senior executive with broad experience in scientific, technical, business and managerial matters in the chemical/ pharmaceutical industry.Klaus has depth knowledge in the field of oncology, CNS, and female health in all aspects of drug development in the US and Europe.He has an extensive management experience in process development and production of chemicals, project, portfolio and alliance management, contract negotiations and technology assessments.Prior to his position at Evestra, Klaus was Corporate Portfolio and Project Management at Schering AG.


Irene Norstedt
European Commission - Head of Sector IMI

Irene Norstedt has been working with various aspects of European Life Sciences research at the European Commission since 1996. She is currently Head of Sector for the implementation of the Innovative Medicines Initiative. Previous responsibilities at the EC have primarily focussed on Small and Medium size Enterprises and industry aspects of biotechnology and health research at European level. Before starting her job in Brussels she worked for BIAcore AB in Uppsala, Sweden. There she had several positions including Business Development for the Drug Discovery and Food Analysis areas and Technical Services Manager. She has also worked as Assistant Technical Attaché at the Swedish Embassy in London. She has an MSc degree from the Royal Institute for Technology in Stockholm.



Jean-Yves Nothias
SGAM - Managing Director Biotechnology Investments

Jean-Yves Nothias (44), Ph.D., Managing Director, leads the BioConvergence Team at SG AM Alternative Investments. Since joining SG AM in 2000, Jean-Yves has built a Team of six professionals. He oversees all portfolio companies and has made significant contributions by bringing in CEOs, syndicating financial rounds and giving strategic advice. Jean-Yves was previously a biotechnology analyst for Hambrecht & Quist based in Paris. Jean-Yves is a board member of Scynexis and GenomeQuest and a supervisory board member of Biosystems International, Cytomics Systems and Genomic Vision.

Jean-Yves earned his PhD in Molecular Biology from Université PM Curie in 1993 and a Masters degree in Management from Université Paris Sorbonne in 1996. During his thesis, he worked at “Institut de Recherche sur le Cancer” in Villejuif and at Wistar Institute in Philadelphia. He started his career in the pharmaceutical industry as a researcher at the Roche Institute of Molecular Biology, Nutley NJ, from 1993 to 1996.

Sam Ogunsalu
Queen Mary Innovation Ltd.- Principal Executive Commercial Development

Samuel has a background in Microbiology and Biochemical Engineering and has experience both as a research scientist, and a pilot plant engineer, as well as significant experience in technology Licensing and international business development. Samuel is also an experienced technology business advisor and has advised private and Aim listed companies in the UK as well small cap US listed companies. At present, Samuel has a key role in out-licensing early and mid stage technology as well as developing new start-up companies and working with the existing start-up portfolio to find solutions and models for sustainability and growth in the current economic climate. Samuel is also Head of Commercialisation and Sector Specialist for Life Sciences for the Knowledge East Partnership, a business-focused network of eight universities and colleges in East London and the Thames Gateway, whose remit is to work with SME companies and help to develop new products and solve problems by devising tailor-made research and consultancy solutions. It also links businesses with academic experts whose skills will benefit these companies, businesses and organisations; it’s partners also collaborate on a range of joint initiatives, turning the latest research and ideas into practical support that benefits organisations of every size and sector.


Christophe Olivier
InnoBioChips - R&D project manager

After a PhD in peptide and protein chemistry, Christophe Olivier was one of the researchers who had started microarrays research projects at the Pasteur Institute of Lille. After 2 years as project leader in a French start-up company he joined the CNRS at the Institut de Biologie de Lille where he has worked in collaboration with the French healthcare industry. In 2008, he was one of the cofounders of InnoBioChips and now he is the scientific director of the society.


Bruno Pagliara
on-kòs Pharma Milano - CEO

On-kòs (  is a consulting firm headquartered in Milan (Italy) and London (UK) supporting all aspects of pharmaceutical planning and execution  for oncology products and speciality pharmaceuticals: preparation and execution of business plans, product and portfolio evaluation, optimisation of product/drug development and regulatory strategies, business development & licensing and marketing and commercialisation .. On-kòs has a network of dedicated product development, marketing, business development and regulatory professionals located in Europe, US and Japan.

Bruno Pagliara started his pharmaceutical career as a sales representative for Hoechst Italia and has acquired over 30 years experience in international pharmaceutical marketing and business development at international headquarter locations with a successful track record in strategic planning and building businesses.

From 1999 to 2007 Bruno was VP Corporate Development of Chiesi Pharmaceuticals, a privately held European multinational company developing novel products and technologies in respiratory, cardiovascular and other niche areas.  During this tenure he finalised more than 15 major transactions.

Prior to Chiesi, Bruno was VP of Corporate Oncology Business Development for Pharmacia and Upjohn located in London and during this period he worked closely in the companies’ integration.

Before joining Pharmacia/Upjohn he held several key roles at Farmitalia Carlo Erba including VP of the Oncology Business Unit; VP Corporate Marketing; Product Group Manager and Product Manager Oncology. During this period Bruno managed a business with over $400M in sales including adriamycin, and co-ordinated the global launches of both epirubicin, and idarubicin.  In addition Bruno supported the launch of camptosar in the US and the line extensions of doxorubicin, increasing the business by over $80M pa, and also launched medroxyprogesterone acetate in breast cancer, a global business of about $100M, plus nicergoline and antibiotics in several countries.


Gérard Papierok
BIO VETO TEST – Scientific Manager

Gérard Papierok is the Founder and Managing Director of BIO VETO TEST. He has 20 years’ experience in Research and Development on new products in the field of in vitro diagnosis and new vaccines.
Gérard started up 2 biotechnology/pharmacy companies and was co-inventor of 6 patents. He is involved in the management of companies, departments and associations in the health/bio sector.Gérard has worked on biotech/health projects for various different ministries and local authorities. He established and managed innovative French and international projects; thus developing various partnerships and establishing international contracts.
Gérard Papierok was involved in setting up clusters, including national health competitive cluster. He is now Honorary Chairman of the Eurobiomed cluster.

Jim Phillips
Vantia Therapeutics - CEO

Dr Jim Phillips, is currently CEO of Vantia Therapeutics, a small molecule R&D spin-out acquired from Ferring in March 2008 with two programs in Phase 2 of clinical development, he also is Chairman of Prosonix Ltd, a specialty nano-particle engineering company for pharmaceuticals. Jim has more than 20 years experience internationally including senior roles at J&J, and Novartis, followed by managing the IPO of Bone Medical in 2004 in Australia, then founding Talisker Pharma with seed capital and building the company until its sale to EUSA Pharma in 2006, Jim was Director General of OPI s.a. after its acquisition by EUSA in 2007, and left EUSA at the end of 2007 to lead the buy-out of Vantia, raising $38m in the process. Jim has worked alongside seed investors and VCs and has experience of the issues and expectations with both types of investment. Jim is a qualified physician with an MBA, and his roles have encompassed Clinical Development, Commercialisation & Business Development activities, as well as fundraisings of over $200m in the last 3 years alone.


Philippe Pouletty
France Biotech - Honorary President

Xavier Regnaut
Innovative Health Diagnostics - CEO

Xavier M. Regnaut, 45 years old, MSc, PgD, Executive MBA, has started his carreer at the CNRS in Roscoff and Gif-sur-Yvette, in algal’s Molecular Biology (B. Kloareg and G. Ducreux’s labs, respectivly). He moved from the academy to the industry in ‘90, as a market manager specialized in diversification and new products and markets (Limagrain Group). He joined Fidesco, international NGO in ’95, as its CEO. He was after that at the creation of a new company in ’99, Novagyn, specialized in gynecology, as project manager, and he ran after for 8 years Reseau Entreprendre Sud-IdF. During this time, he has created a special fund dedicated to Biotech’s in the Paris area, Biotech Entreprendre.

He is from the end of ’08 co-founder and CEO of Innovative Health Diagnostics, new venture company specialized in the development of neurological’s biomarkers of Alzheimer decease, located in Strasbourg.


Fred Reinhart
Association of University Technology Managers - Vice President

Fred Reinhart has served at Vice President for Finance of the Association of University Technology Managers (AUTM), since 2006.  AUTM is a leading international membership organization of over 3200 technology transfer and licensing professionals.  He is also Treasurer of the AUTM Foundation.  He was previously Associate Vice President for Research and Technology Commercialization at Wayne State University (WSU) from 1996 until 2009.  In that position, he managed several programs including Venture Development (start-up companies), Technology Transfer (licensing), and economic development initiatives.  He also served on the board and executive committee for TechTown, WSU’s Research and Technology Park, and was Chairman of the Board of Directors for the Michigan Biosciences Industry Association (MichBio) during the period of 1998-2005

Mr. Reinhart has 24 years experience in technology transfer at WSU, New England Medical Center in Boston, and the University of Michigan.  He is a graduate of the University of Michigan with a bachelor’s degree and MBA degree in New Product Development and Marketing.


Remy Renaudin
Eureka - French National Project Coordinator

Rémy Renaudin is the French EUREKA National Project Coordinator (NPC) since 2005, appointed by the French Ministers in charge of Research and Industry. As NPC, he is in direct contact with project participants – and potential project participants - in France in order to facilitate the setting-up and running of projects.
Rémy Renaudin has been Chairman of the NPC Group during the second French Chairmanship of EUREKA in 2003-2004. He has a long experience of European and transnational cooperation. From 1999 to 1992, Mr Renaudin has worked for the Financial Direction of the Ministry for Foreign Affairs. He has also been working in French embassies in Somalia, Kenya, Netherlands and Finland.
Married, father of three children, he was born in Burgundy and is 55 years old.


Robert Sarisky
Johnson & Johnson Pharmaceuticals, LLC - Vice President, External Research & Early Development

Rob Sarisky, PhD, MBA, is Vice President of External Research and Early Development within Johnson & Johnson Pharmaceuticals.  In this role, he is responsible for building an innovative and high value product portfolio by establishing partnerships with leading academic institutions, drug discovery accelerators, biotechnology companies and not-for-profit institutions.  Prior to his current role, Rob was Director of Virology at GlaxoSmithKline Pharmaceuticals and Sr. Director of Immunobiology Research at Centocor R&D.

Rob received his Ph.D. in Genetics at the Pennsylvania State University College of Medicine, completed his postdoctoral training at the Johns Hopkins School of Medicine, and holds an MBA in Marketing from Lehigh University.  He has authored more than 100 publications and patents, serves on the Editorial Board for two scientific journals, is a member of the University of Pennsylvania Executive Advisory Committee for the HHMI Graduate Training in Medical Sciences and the University of Miami Innovation Corporate Advisory Council, and is an adjunct Professor for Drexel University School of Medicine in the Department of Microbiology and Immunology.


Markus Schmidt
Organisation for International Dialogue and Conflict Management - Coordinator Synbiosafe project

Dr. Markus Schmidt, is co-founder and board member of IDC ( and leader of the IDC biosafety working group.

He has a background in electronic engineering (undergraduate), biology (M.Sc), risk assessment and risk perception of new biotechnologies (PhD). He has contributed and coordinated several research projects on management of plant genetic resources and ethical, legal and social aspects of novel biotechnologies. In the last years he worked on safety, security and ethical issues in synthetic biology, coordinating the European project SYNBIOSAFE ( that lead to several publications1 including a book on the societal consequences of synthetic biology2. In his work in SYNBIOSAFE he focused on biosafety and risk assessment challenges of synthetic biology, a subject that he will continue to explore in a joint Austrian-Chinese project (2009-2012). In another European project called TARPOL he investigates the potential socio-economic impact of synthetic biology in the area of industrial biotechnology ( He also started to assess the role of the media in communicating synthetic biology and how it be perceived by laypeople in Europe ( He was part of the international scientific advisory board of the Synthetic Biology 3.0 conference 2007 in Zurich, Switzerland, and organising committee chair for the ESF conference on synthetic biology ECSB II, 2009, in Sant Feliu de Guixol, Spain. Currently he is member of the Expert Advisory Group of the J Craig Venter Institute (JCVI) project entitled “Synthetic Genomics: Scientists’ Understanding of Society’s Concerns, Society’s Understanding of the Science and Scientists“. He is also the editor of a special issue for the peer review journal “Systems and Synthetic Biology” on societal issue in synthetic biology.


1 See:

2 Book: Synthetic Biology. The Technoscience and its Societal Consequences. Schmidt, M.; Kelle, A.; Ganguli, A.; de Vriend, H. (Eds.) 2009. Springer. ISBN: 978-90-481-2677-4. See:


Carina Schmidt
Athera Biotechnologies AB - CEO

Carina Schmidt has over 25 years industrial experience, mainly in business development and management, international marketing and product management within the biotech area. Ms Schmidt has a broad commercial experience from development of new business opportunities for life science technologies. She holds a M.Sc. (Chem. Eng., 1982) from Royal Institute of Technology in Stockholm.

Carina Schmidt is CEO of Athera Biotechnologies AB since 2007. Athera develops novel products for cardiovascular disease (CVD) treatment and prevention, targeting the immunological components in atherosclerosis, the inflammatory process leading to CVD. Athera is part of the Karolinska Development AB (publ) portfolio. The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. The products candidates are first-in-class biopharmaceuticals targeting Acute Coronary Syndrome. Annexin A5 is a recombinant protein to prevent inflammation and new thrombosis. PC-mAb is a monoclonal antibody to prevent secondary cardiovascular events, aimed at restoring levels of the natural antibody to phosphorylcholine (anti-PC).  CVDefine® is a CE-marked kit for detecting antibodies to PC in human blood and is targeting use to select high-risk patients for ACS treatment.

Carina Schmidt is also board director of Genovis AB (publ), delegate in the investment committee of Innovationsbridge Mitt (regional seed investor), as well as teaches a Ph.D. course in ”Enrepreneurship in Biotechnology” at Umeå University. Ms Schmidt has former experience from positions as management consultant, interim CEO and business advisor to several biotech start-ups. During years 1985 to 2000 she has worked with Pharmacia Biotech/Amersham Biosciences (now GE HealthCare), founded Grasp Bioscience AB in year 2000 and co-founded management consultant network BioBusiness Partners Scandinavia in year 2006. She has an extensive international and executive level network.


Noam Shani
Kahr Medical - CEO

Dr. Shani is the CEO of KAHR Medical. KAHR is pioneering the development of TSCP-based drugs; a new platform technology licensed from the University of Pennsylvania. TSCP drugs are fusion proteins with two functional ends; the first-in-class drugs to convert inter-cellular signals.

Before joining KAHR Medical, Dr. Shani was Vice President of R&D for Medgenics (AIM: MEDG) and for Compugen (NASDAQ: CGEN). He received both his Master's and Ph.D. from the Weizmann Institute of Science in Israel, and did his postdoctoral fellowship at the Johns Hopkins School of Medicine in Baltimore, USA.


Dave Smardon
Bioenterprise Corporation - President and Director

Dave Smardon is President & CEO and a Director of BioEnterprise Corporation, Canada’s leading agricultural business accelerator. Focused on building ag-bio based businesses, the organization sees world-class innovations commercialize with the help of BioEnterprise’s strategic know-how.  Mr. Smardon is a seasoned executive with a background in establishing, growing, and financing companies.  He has the insight and outlook to confidently say agri-technology is a “New Wave” of investment opportunity.
Mr. Smardon campaigns on behalf of the interests of Canadian entrepreneurs, and strives to help build a venture capital industry in Canada that is both sustainable and active.  He advises on a number of government funding programs, volunteers for several associations, and serves as a Board Member for more than a half-dozen companies to which he is an angel investor.
Mr. Smardon began his career as a successful entrepreneur in the eighties, when he established educational software company Learning Connections.  He then founded Commcorp Technologies Inc., a spin-off company providing technology outsourcing.  Later, throughout the nineties, Mr. Smardon dedicated himself to his venture capital and investment activities.  He established and grew the Nibiru group of companies (Nibiru Tactical Corporation, Nibiru Investments, Nibiru Capital Management Limited and Nibiru Corporate Finance Inc.).
Throughout his career, Mr. Smardon has held positions at industry leading companies (Texas Instruments Inc., Unisys Corporation, Meridian Technologies and Apple Computer Inc.).  At Apple, he led the Canadian arm of Apple Computer's venture capital group, where he invested in 35 Canadian companies delivering exceptionally high returns (43% ROI). During this time, Mr. Smardon developed strong ties into the venture capital, investment banking and angel communities, in both the USA and Canada.
Over the years Mr. Smardon has developed a good reputation, and is well known within the Canadian venture capital industry and angel community.  The solid partnerships he’s created and prosperous investments he’s made, speak to Mr. Smardon’s wisdom as both a strong communicator and respected industry expert.


Daniel Spasic

Daniel Spasic started his career in the pharmaceutical industry in 1993 by joining Pharmacia & Upjohn in Lund, Sweden. He served in the Medical Department working with clinical development mainly in therapeutic areas such as CNS and oncology in both Sweden and Italy. In 1996, he founded TFS Trial Form Support a clinical contract research organisation (CRO) with a strong and dedicated focus in the area of clinical trials from phase I, II and III. Under his guidance, TFS has become the largest non-listed European clinical CRO with 500 employees and a net revenue of 38 million €, serving pharmaceutical and biotechnological companies in their clinical drug development process. He is an active member of the Drug Information Association (DIA), SwedenBio and Medicon Valley Alliance. He is also a member of the Board of Medicon Valley Alliance - one of the strongest bioregions in Europe. Daniel holds a technical degree in chemical engineering.

Ulrich Stottmeister
International Society of Environmental Biotechnology – Board Member

Ulrich Stottmeister is retired professor for biotechnology and technical chemistry and currently has a guest-status at the Helmholtz-Centre for Environmental Research, UFZ. He studied chemistry at the University of Leipzig (Germany), received his diploma in chemistry in 1964 and his PhD in 1968. He was working as scientific co-worker at the Institute of Biotechnology of the Academy of Sciences of the GDR and received his Dr. sc. nat. in 1986. Since then he was lecturer at the University of Leipzig for biotechnology (Facultas docendii in 1987, Dr. habil. in 1991). He was working as assistant professor at the University of Waterloo, Canada in 1991. In 1992 he started to build up the research group for Remediation Research in the newly founded UFZ - Centre for Environmental Research in Leipzig as department head. In 1995 he was appointed to the rank of a full professor of the faculty of Chemistry and Mineralogy at the University of Leipzig. From 1997 to 2002 he served as scientific advisor of the Federal Ministry for Education and Research for the German-Canadian Co-operation in Environmental Research. Currently he is leader of the group “Technology Assessment” at the Saxony Academy of Sciences and lecturer at the Technical University of Dresden.

Ulrich Stottmeister is full member of the Saxony Academy of Sciences since 1996 and since 2002 full member of acatech, the German Academy of Technical Sciences. From 2004 to 2008 he was vice-president and president of ISEB - International Society of Environmental Research. His general fields of interest are Environmental Biotechnology and “White” Biotechnology. He is author, co-author and editor of a large number of publications, monograph contributions and books and holds several patents.


Adam Svobodnik
ADDS - Country Manager

Dave Tapolczay

Dr David Tapolczay has 21 years experience of R&D management; his past roles include joint worldwide head of chemistry for Zeneca agrochemicals and senior manager of chemical development for Glaxo. He was responsible for the rapid growth of Cambridge Discovery Chemistry and was a key figure in two successful sales of the company initially to Oxford Molecular and then Millennium Pharmaceuticals. Post this last acquisition David was VP of Pharmaceutical Sciences with responsibility for over 230 scientists. On leaving Millennium David was a founder of Pharmorphix Ltd which was acquired by Sigma Aldrich Fine Chemicals in August 2006. He has also been involved with the start up of 5 companies all of which are still trading and one of which has been AIM listed. He was most recently VP of Technology Development for GSK pharmaceuticals and is currently the Chief Executive Officer of the Medical Research Council Technology Group (MRCT).

David has an international reputation in the pharmaceutical chemical development as well as an outstanding academic track record with a considerable number of patents and publications. He was a visiting Professor at Sussex University and has previously held the position of visiting lecturer at Nottingham, Reading and Durham Universities and a member of both the Technical Opportunities Panel and the User Panel of the EPSRC.


Bernard Thorens
Lausanne University - Professor

Bernard Thorens studied at the University of Geneva and at the Whitehead Institute of Biomedical Research in Cambridge (MA). He is now a Professor of Physiology at the Department of Physiology and Center for Integrative Genomics at the University of Lausanne. His research focuses on the molecular control of glucose and energy homeostasis and of metabolic diseases, using molecular and integrated physiology approaches.  His special interests are on the function of the pancreatic islets and their function in whole body physiology and on the regulation by nutrients of liver and brain functions. Dr. Thorens has authored and co-authored more than 140 full papers and review articles in peer-reviewed international journals and he is or has been on the editorial board of several scientific journals and on the board of several national or international funding agencies. His research has been recognized by national and international awards. He was a founder of the biotechnology company Modex Therapeutics.

Dr Thorens has been partner of several EU integrated projects and is deputy coordinator of the EU project EuroDia “Functional genomics of pancreatic beta cells and of tissues involved in control of the endocrine pancreas for prevention and treatment of type 2 diabetes”. He coordinated the successful application to the IMI project IMIDIA : Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes.


Patrick Tricoli
Sanofi-Aventis - R&D, External Innovation Department, Access to Innovation Europe Head

Before joining the group in 1991 as project manager in pharmacotoxicology, Patrick Tricoli was within a CNRS laboratory in 1986 where he was focused on neuropharmacology and then within the medical research division of Lederle Laboratories (USA), in 1989.In 1996, he joined the company’s headquarters in Paris to head up the Promotion of Research and Technology and became, in 2002, Director of Corporate Promotion of Innovation. After 2004, he was Director of Valorization & Innovation for sanofi-aventis. From 2007 to 2009, he was Global Deputy Head of Partnering and Innovation Department.

In March 2009, he has been appointed Head of Access to Innovation Europe in ‘R&D External Innovation’ organization.  Patrick is also member of the IMI governance task force and responsible for IMI global office for sanofi-aventis.

Patrick Tricoli is a doctor in Pharmaceutical Sciences, has a Masters in Pharmacology and an Executive MBA.

Hans Van Der Saag
BioActor - Managing Director

Hans is the founder and managing director of BIOACTOR, a technology company focussing on the validation and development of proprietary bioactives for functional food. He previously co-founded and was for 6 years the COO of CropDesign, the largest independent agbiotech compnay in Europe. CropDesign was successfully sold to BASF. Previously, he worked in corporate legal and business development roles with Monsanto and ICI. Hans has a Master of Laws from Leiden University and an MBA from Bradford University. He was a Research Fellow with Max Planck Institute for Intellectual Property Law in Munich.


Max van Min
FlexGen - Marketing & Sales Manager

Max van Min is Marketing & Sales Manager of FlexGen B.V., a Dutch start-up based in the Leiden Bioscience Park. In this capacity he is responsible for FlexGen’s communication and commercialization of the FlexArrayer, an instrument for flexible and fast custom micro-array synthesis. In this role he also identifies academic partners of interest and sets up and manages scientific collaborations with the aim of co-developing innovative high quality products for genetic research.
Max has previously worked as International Business Development Manager of the Royal Cebeco Group, as Marketing & Sales Manager of the genetic research company Keygene and as Product Manager of the Life-Science multinational DSM.
 Max has a degree in Biotechnology from Wageningen University, the Netherlands.


Philip Vanek
Lonza Bioscience - Cell Therapy, Head of Business Development

Dr. Vanek joined Lonza as Head of Business Development, Cell Therapy in October of 2007.  In this capacity, he has worked with many emerging-stage therapeutic companies to help support their development of scalable commercialization strategies.  Prior to joining Lonza, he was Director of Global Marketing for BD Biosciences’ Bioimaging Systems group formed following the acquisition of Atto Bioscience by Becton Dickinson in July of 2004. At Atto, he was Director of Corporate Development responsible for product commercialization and business development. Prior to joining Atto Bioscience in 2001, Phil directed the Functional Genomics and Proteomics business unit at Life Technologies (Gibco/BRL), now part of Invitrogen.

Phil received his Ph.D. in Biochemistry from Georgetown University Medical Center in Washington, DC, and subsequently held an IRTA fellowship at the National Cancer Institute in the Laboratory of Molecular Oncology directed by Dr. Takis Papas.  He continued his post-doctoral training at the Hollings Cancer Center at the Medical University of South Carolina in Charleston, in the Center for Molecular and Structural Biology.

Phil is an instructor for Johns Hopkins University Advanced Academic Programs and has lectured at Georgetown University School of Medicine in the Masters of Biotechnology Program.  He has also chaired sessions for a number of local and international meetings in biotechnology.



Oliver Wiedemann
EpiCept GmbH - Director of Medical Affairs

Oliver Wiedemann, M.D., joined our subsidiary EpiCept GmbH in October 1998 as Director of Medical Affairs. Since July 1999, he has been the Managing Director at EpiCept GmbH. From January 1992 until joining us, he was the Department Head CNS/ Muscle of the Medical Department of Sanofi Winthrop, Munich. Prior to that, Dr. Widemann worked as a surgeon at the Olympiapark-Klinik, Munich. He is the author of several scientific publications in the pain area. Dr. Wiedemann received his Medical Doctorate Degree from the University of Munich.

Alain Yvorra
Eurobiomed - Managing Director

Alain Yvorra is currently managing director of the health cluster Eurobiomed that gathers the actors of the Life Science along the French Mediterranean border. Prior to joining Eurobiomed in 2007, he was an international healthcare consultant specialized in organization, evaluation and monitoring for medical laboratories and hospitals. He also served as Managing Director at Covalab/Epytop, a R&D biotechnology company. Previous to this role, he was general counsel for patents at Synt:em SA a biopharmaceutical drug discovery company where he directed intellectual property efforts for the company’s research products and where he was responsible for the management of the company’s legal affairs. Alain Yvorra has also served as senior business development at Beckman Instruments. Alain Yvorra has a PhD in Biology from the University Pierre & Marie Curie of Paris.

Richard Zimmerman
IBA - Vice President Radiopharmaceutical Development

Richard Zimmermann is a chemistry engineer and PhD in Organic Chemistry (Strasbourg, F) with a post-doc at Georgetown University, Washington DC, who spent almost 15 years working with the conventional pharmaceutical industry in the research departments of Beecham (F - cardiology) and Solvay Pharma (F, D, NL – immunology, then gastroenterology) before joining as Director of R&D the Radiopharmaceutical Industry with CIS bio international (Saclay, F), later a subsidiary of Schering Pharma. For three years he was also in charge of building the European PET manufacturing centers for CIS/IBA and he is now VP Radiopharmaceutical Development for IBA Molecular. He has been leading the AIPES PET working group for 3 years. So far he did spend 10 years in the Nuclear Medicine environment and he published recently a general audience book on that topic in French, English and Spanish.

© EuroBio 2009 | Credits | edikka
Co-organisers: |